Original Article
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
N Engl J Med 2004; 350:2343-2351June 3, 2004
- Abstract
Background
The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL). Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting.
Methods
We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with oxaliplatin for six months. The primary end point was disease-free survival.
Results
A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9 months, 237 patients in the group given FL plus oxaliplatin had had a cancer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group given FL plus oxaliplatin and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus oxaliplatin, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six patients in each group died during treatment (death rate, 0.5 percent).
Conclusions
Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Media in This Article
Figure 1
Kaplan–Meier Estimates of Disease-free Survival in the Group Given Fluorouracil and Leucovorin (FL) and the Group Given FL plus Oxaliplatin, According to the Intention to Treat.Figure 2
Kaplan–Meier Estimates of Disease-free Survival in the Group Given Fluorouracil and Leucovorin (FL) and the Group Given FL plus Oxaliplatin, According to the Stage of Disease and the Intention to Treat.Article Activity
- Article
Colorectal cancer is the second leading cause of death from cancer in Western countries1; 40 to 50 percent of patients who undergo potentially curative surgery alone ultimately relapse and die of metastatic disease.2 The most important prognostic indicator of survival in early colon cancer is the stage of the tumor (T, according to the tumor–node–metastasis [TNM] classification), determined by the depth of penetration through the bowel wall, and the number of involved lymph nodes.3
The demonstration that postoperative adjuvant treatment with fluorouracil and levamisole reduced the mortality rate by 33 percent among patients with stage III colon cancer4 prompted several trials, which established six months of treatment with fluorouracil plus leucovorin (FL) as the standard adjuvant chemotherapy for stage III colon cancer.5-11 Oxaliplatin is a third-generation platinum derivative, which, when combined with fluorouracil and leucovorin, is among the most effective chemotherapies for metastatic colorectal cancer.12-15 To determine whether oxaliplatin can also benefit patients with disease in an earlier stage, we conducted an international phase 3 clinical trial in patients with stage II or III colon cancer — the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC).
Methods
Patients
Patients were eligible if they had undergone complete resection of histologically proven stage II (T3 or T4,N0,M0) or stage III (any T,N1 or N2,M0) colon cancer, as defined by the presence of the inferior pole of the tumor above the peritoneal reflection — that is, at least 15 cm from the anal margin. Treatment had to be started within seven weeks after surgery. Other eligibility criteria included an age of 18 to 75 years; a Karnofsky performance-status score of at least 60; a carcinoembryonic antigen level of less than 10 ng per milliliter; the absence of prior chemotherapy, immunotherapy, or radiotherapy; and adequate blood counts and liver and kidney function. Written informed consent was required from all patients, and the study was approved by the ethics committees of the participating centers.
Treatment
Eligible patients were randomly assigned to receive FL alone or with oxaliplatin. In the FL group, each cycle comprised a 2-hour infusion of 200 mg of leucovorin per square meter of body-surface area followed by a bolus of 400 mg of fluorouracil per square meter and then a 22-hour infusion of 600 mg of fluorouracil per square meter given on 2 consecutive days every 14 days, for 12 cycles. In the group given FL plus oxaliplatin, the same FL regimen was used, plus a two-hour infusion of 85 mg of oxaliplatin (Eloxatin, Sanofi-Synthelabo) per square meter on day 1, given simultaneously with leucovorin, with the use of a Y infusion device. The use of disposable pumps (LV5 infusors, Baxter Healthcare) allowed outpatients to receive a continuous infusion of fluorouracil.
Adverse effects were graded according to the Common Toxicity Criteria of the National Cancer Institute, version 1. According to these criteria, a score of 1 indicates mild adverse effects, a score of 2 moderate adverse effects, a score of 3 severe adverse effects, and a score of 4 life-threatening adverse effects. Dose reductions were based on the worst adverse effects observed during the previous cycle. The dose of oxaliplatin was to be reduced to 75 mg per square meter in the event of persistent (at least 14 days) paresthesias, temporary painful paresthesias, or functional impairment. Oxaliplatin was discontinued in cases of persistent painful paresthesias or functional impairment. Together with reductions in the dose of oxaliplatin, the bolus dose of fluorouracil was reduced to 300 mg per square meter and the infusion to 500 mg per square meter in the event of grade 3 or 4 neutropenia or thrombocytopenia (or both), diarrhea, stomatitis, or other drug-related adverse effects of grade 3. Only the dose of fluorouracil was scheduled to be reduced in the event of skin-related adverse effects of grade 3 or 4. Treatment was delayed by up to three weeks until the patient recovered from various adverse effects, the neutrophil count exceeded 1500 per cubic millimeter, and the platelet count exceeded 100,000 per cubic millimeter. Chemotherapy was stopped in the event of cardiac or neurocerebellar adverse effects or grade 3 or 4 allergic reactions.
Follow-up
Patients were assessed before randomization, every two weeks during treatment, and then every six months for five years. The baseline assessment involved a medical history taking, physical examination, biologic tests, measurement of the carcinoembryonic antigen level, chest radiography, and abdominal ultrasonography or computed tomography. Patients were monitored for adverse effects throughout the treatment period and until 28 days after the last cycle of chemotherapy, unless treatment-related adverse effects required additional follow-up.
The diagnosis of recurrence was made on the basis of imaging and, if necessary, cytologic analysis or biopsy. An elevated carcinoembryonic antigen level as a solitary finding was not accepted as evidence of relapse. Neurologic adverse effects were to be reported at each visit during follow-up and were assessed with the use of the neurosensory section of the Common Toxicity Criteria of the National Cancer Institute, version 1.
Statistical Analysis
Randomization was performed centrally, and the minimization method was used to balance treatment allocation according to the TNM stage (T2 or T3 vs. T4 and N0, N1, or N2), the presence or absence of bowel obstruction or tumor perforation, and the medical center. The sample size of 2200 patients was calculated under the assumptions of a three-year disease-free survival rate of 73 percent in the control group and 79 percent in the group given FL plus oxaliplatin, with a ratio of stage II disease to stage III disease of 0.4:0.6, an enrollment period and a follow-up period of three years, a decrease in the risk of relapse after three years, a statistical power of 90 percent, and an alpha value of 0.05 and two-sided P values derived with the use of the log-rank test. The primary efficacy variable was disease-free survival, defined as the time from randomization to relapse or death, whichever occurred first. Second colorectal cancers were considered relapses, whereas noncolorectal tumors were disregarded in the analyses.
The primary statistical analysis of efficacy was the comparison, after three years of follow-up, of disease-free survival between groups according to the intention-to-treat principle, with the use of a two-sided log-rank test stratified according to baseline disease stage. Hazard ratios and 95 percent confidence intervals were calculated with the use of the Cox proportional-hazards model. Survival curves were drawn according to Kaplan–Meier methods.
To assess the consistency of the effect of treatment on disease-free survival across prognostic subgroups, we calculated hazard ratios and 95 percent confidence limits for subgroups defined according to the following variables: sex, age, disease stage (II vs. III), baseline serum carcinoembryonic antigen level, number of involved lymph nodes (≤4 vs. >4), T classification (T4 vs. T1, T2, or T3), degree of cellular differentiation (well vs. poorly differentiated), and the presence or absence of perforation, obstruction, and venous invasion.
The cutoff date of the analysis was April 22, 2003. The duration of follow-up was defined as the number of months from randomization to the cutoff date.
Secondary end points were safety, including long-term adverse effects, and overall survival, measured from the time of randomization to death from any cause. With a median follow-up of three years, it is too early to compare the two treatment groups statistically in terms of survival, and only descriptive analyses of overall survival are presented. Safety analyses included patients who had received at least one cycle of treatment.
Organization of the Trial
The concept underlying this study was developed by Dr. de Gramont, and the investigation was designed by the investigators and Sanofi-Synthelabo. Data were collected, managed, and analyzed by the sponsor. The article was written by the investigators, on the basis of data and statistical analyses provided by Sanofi-Synthelabo.
A data and safety monitoring board of independent experts reviewed safety data every six months during the treatment period to provide the sponsor with independent advice on the progress of the study and on safety. No interim analysis was planned or performed.
Results
Study Population
Between October 1998 and January 2001, 2246 patients were enrolled at 146 centers in 20 countries: 1123 patients were randomly assigned to receive FL plus oxaliplatin and 1123 to receive FL without oxaliplatin. Of these patients, 1108 received at least one cycle of FL plus oxaliplatin and 1111 received at least one cycle of FL. The patients' characteristics were well matched in the two groups (Table 1Table 1
Baseline Characteristics of the Patients in the Group Given Fluorouracil and Leucovorin (FL) plus Oxaliplatin and the FL Group.). In both groups, 60 percent of the patients had stage III disease and 40 percent had stage II disease. The overall median time between surgery and the start of chemotherapy was 5.7 weeks (range, 1.1 to 17.0).A total of 41 patients (1.8 percent) did not strictly meet eligibility criteria related to baseline disease. In one patient in each group, the resection of primary tumor was incomplete. Four patients in the group given FL plus oxaliplatin and six in the FL group had a history of cancer, including colorectal cancer. Thirteen patients (four in the group given FL plus oxaliplatin and nine in the FL group) had stage IV cancer, and three patients (two in the group given FL plus oxaliplatin and one in the FL group) had cancer of the middle or lower rectum. Four patients in the group given FL plus oxaliplatin and nine in the FL group had various other eligibility-criteria violations.
Chemotherapy
The median number of cycles of chemotherapy received was 12 in both groups; 74.7 percent of patients in the group given FL plus oxaliplatin and 86.5 percent in the FL group received the planned 12 cycles. In the group that received FL plus oxaliplatin, the median dosage of oxaliplatin was 34.2 mg per square meter per week across all cycles received and 36.5 mg per square meter per week across cycles including oxaliplatin. In both cases, more than 80 percent of the planned dose was actually given (80.5 percent and 85.9 percent, respectively). The dose of fluorouracil received was 84.4 percent of the planned dose in the group given FL plus oxaliplatin and 97.7 percent of the planned dose in the FL group.
Safety
Neutropenia, diarrhea, and vomiting were the most frequent grade 3 or 4 adverse effects in the group given FL plus oxaliplatin (Table 2Table 2
Adverse Events in the Group Given Fluorouracil and Leucovorin (FL) plus Oxaliplatin and the FL Group.). Grade 3 or 4 neutropenia was much commoner with FL plus oxaliplatin than with FL (41.1 percent vs. 4.7 percent, P<0.001) but was complicated by fever or infection in only 1.8 percent of cases (20 patients) in the group given FL plus oxaliplatin and in 0.2 percent of cases (2 patients) in the FL group (P<0.001). The incidence of thromboembolic events among patients who received at least one cycle of the assigned regimen was similar in the two groups (63 of 1108 patients [5.7 percent] and 72 of 1111 patients [6.5 percent], respectively).Although 92.1 percent of patients treated with FL plus oxaliplatin had peripheral neuropathy during treatment, half of these episodes were of grade 1 (Table 3Table 3
Incidence of Neurosensory Symptoms during Treatment and Follow-up in the Group Given Fluorouracil, Leucovorin, and Oxaliplatin.). Of the 137 patients (12.4 percent) who had grade 3 peripheral neuropathy during treatment, grade 3 symptoms were still present in 8 patients at the six-month follow-up visit and in 5 patients at the one-year visit. In 12 patients, grade 3 peripheral neurosensory symptoms appeared after the end of treatment, and 6 of these patients had persistent grade 3 symptoms after one year. In total, 11 of 1018 patients (1.1 percent) who were assessed one year after the end of treatment continued to have grade 3 peripheral neurosensory symptoms. This number dropped to five (0.5 percent) after 18 months (Table 3).Twelve patients — six in each group (0.5 percent) — died within 1 month after the end of treatment; these included three deaths in each group during the first 60 days of treatment. In the group given FL plus oxaliplatin, four patients died of infection or sepsis (two with neutropenia) and two of intracranial hemorrhage. In the FL group, one patient each died of sepsis, Stevens–Johnson syndrome in the context of severe diarrhea and fluconazole treatment, and anoxic cerebral infarction; one patient committed suicide; and two died suddenly from cardiac causes.
Follow-up
There was good compliance with follow-up visits. The mean time between visits was 5.97 months in the group given FL plus oxaliplatin and 5.98 months in the FL group. The median interval was 6.01 months in both groups.
Disease-free Survival
At the time of analysis (median follow-up, 37.9 months), 237 patients in the group given FL plus oxaliplatin (21.1 percent) had relapsed or died, as compared with 293 (26.1 percent) in the FL group. The hazard ratio for recurrence in the group given FL plus oxaliplatin, as compared with the FL group, was 0.77 (P=0.002), corresponding to a 23 percent reduction in the risk of relapse. The probability of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7 percent) in the group given FL plus oxaliplatin and 72.9 percent (95 percent confidence interval, 70.2 to 75.7 percent) in the FL group (P=0.002 by the stratified log-rank test) (Table 4Table 4
Analysis of Disease-free Survival According to the Intention-to-Treat Principle. and Figure 1Figure 1Kaplan–Meier Estimates of Disease-free Survival in the Group Given Fluorouracil and Leucovorin (FL) and the Group Given FL plus Oxaliplatin, According to the Intention to Treat.).Among patients with stage III disease, the hazard ratio for relapse was 0.76 (95 percent confidence interval, 0.62 to 0.92) in the group given FL plus oxaliplatin, as compared with the FL group, and the three-year disease-free survival rate was 72.2 percent and 65.3 percent, respectively (Figure 2Figure 2
Kaplan–Meier Estimates of Disease-free Survival in the Group Given Fluorouracil and Leucovorin (FL) and the Group Given FL plus Oxaliplatin, According to the Stage of Disease and the Intention to Treat.). Among patients with stage II disease, the hazard ratio for relapse was 0.80 (95 percent confidence interval, 0.56 to 1.15) in the group given FL plus oxaliplatin, as compared with the FL group, and the three-year disease-free survival rates were 87.0 percent and 84.3 percent, respectively (Figure 2).A Cox-model analysis showed that the reduced risk of recurrence with FL plus oxaliplatin was similar in patients with stage II and those with stage III disease (P=0.77). Calculation of hazard ratios and 95 percent confidence intervals (Figure 3Figure 3
Hazard Ratios and 95 Percent Confidence Intervals for Recurrence in the Group Given Fluorouracil and Leucovorin (FL) plus Oxaliplatin, as Compared with the FL Group, According to Baseline Prognostic Factors and the Intention to Treat.) showed that the reduced risk of relapse was consistent in all subgroups defined on the basis of prognostic factors at baseline.Overall Survival
At the time of the cutoff date of the primary analysis, 133 patients had died in the group given FL plus oxaliplatin, as compared with 146 patients in the FL group (hazard ratio for death, 0.90; 95 percent confidence interval, 0.71 to 1.13), and the probability of survival at three years was 87.7 percent and 86.6 percent, respectively. Most of the patients who died had stage III disease (104 in the group given FL plus oxaliplatin and 119 in the FL group); the hazard ratio for death in this subgroup was 0.86 (95 percent confidence interval, 0.66 to 1.11).
Discussion
In previous trials, the addition of oxaliplatin to fluorouracil and leucovorin doubled the response rate and prolonged progression-free survival among patients with metastatic colorectal cancer.14 The efficacy and safety of this regimen were recently confirmed in a large, randomized, phase 3 trial, which found that this approach was superior (with respect to all efficacy variables, including overall survival) to the combination of irinotecan, fluorouracil (given as a bolus), and leucovorin.15 Our trial was designed to test the efficacy of adjuvant treatment with the regimen of FL plus oxaliplatin. We chose disease-free survival as the primary end point of the study because, like others,16 we believe that the absence of relapse is the best indicator of efficacy, since it relates directly to the effect of the treatment under investigation. By allowing early appraisal of the results, the use of three-year disease-free survival as the primary end point for adjuvant trials of patients with colon cancer should permit rapid evaluation of new treatments. Whether disease-free survival should be a primary end point is still under discussion, but a recent analysis of several studies supports the appropriateness of the use of three-year disease-free survival as a good predictor of five-year overall survival in trials of adjuvant treatment of colon cancer.17
Disease-free survival in the FL group in our study falls within the highest range reported in most studies of adjuvant treatment of colon cancer with FL.6-8,18,19 The improvement in disease-free survival among patients who were treated with FL plus oxaliplatin corresponds to a relative reduction in the risk of recurrence of 23 percent. Since most relapses after curative surgery occur within the first three years, we consider our results in this respect to be complete.
Although it is agreed that patients with stage III disease benefit from adjuvant treatment, whether all patients with stage II disease should receive such treatment remains debatable. This controversy was sustained for years by the contradictory conclusions of two large groups of investigators. The National Surgical Adjuvant Breast and Bowel Project concluded that the relative benefits of treatment were largely the same for stage II and stage III tumors,20 whereas the International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) failed to demonstrate a statistically significant benefit for stage II tumors.21
A recent meta-analysis from the Mayo Clinic,22 which evaluated individual data on 3300 patients who were enrolled in five randomized trials, including those analyzed in IMPACT B2, concluded that patients with stage II disease could benefit from adjuvant chemotherapy, but to a lesser extent than patients with stage III tumors. Indeed, the absolute benefit among patients with stage II disease is only half as great as that among patients with stage III disease, and twice as many patients with stage II tumors are required in such studies in order to detect a difference.
A test for interaction is an appropriate statistical approach to the question of whether the benefit of adjuvant treatment differs between stage II and stage III colorectal cancer.23 In our study, this test showed no significant interaction between the stage of disease and the treatment, indicating that FL plus oxaliplatin benefited both stage II and stage III colorectal cancer. From a clinical standpoint, stage II colon cancer occurs in a heterogeneous, node-negative population in which clinical and biologic prognostic factors other than the status of lymph-node involvement need to be taken into account. Tools are being developed to help physicians assess the risk–benefit ratio of adjuvant chemotherapies for individual patients.22
With no clear consensus on the most effective FL regimen to be used for adjuvant treatment, we chose a twice-monthly regimen because of its efficacy and low rates of adverse effects in patients with advanced colorectal cancer, alone and in combination with oxaliplatin.12,14,24 Supporting our decision are recent results demonstrating that this approach to adjuvant therapy is less toxic than monthly bolus injections of FL and is just as effective.18 This approach led to a straightforward study design, since the treatment in both groups was similar except for the addition of oxaliplatin in the group given FL plus oxaliplatin. The improved disease-free survival in the FL-plus-oxaliplatin group is thus directly linked to oxaliplatin.
The main safety concern regarding the use of oxaliplatin is peripheral neuropathy. Oxaliplatin induces frequent, transient, distal paresthesias during or shortly after the first minutes of infusion. In some cases these neurosensory symptoms increase in intensity with cumulative doses, persist between cycles, and interfere with function (in the case of grade 3 effects).12,14,25 We observed grade 3 peripheral neuropathy in 12.4 percent of patients who were receiving oxaliplatin. At one year, 11 patients (1.1 percent) had grade 3 neuropathy. Among them, two were found to have underlying disease that could have caused these symptoms (diabetes and hemiplegia, respectively). Although more frequent among patients receiving FL plus oxaliplatin than among those treated with FL alone, grade 3 or 4 neutropenia led to fever or infection in only 1.8 percent of patients in the former group. Similar findings have been reported among patients with metastatic colorectal cancer.14 From a safety standpoint, the rate of death from any cause was similarly low during treatment in both groups and, at 0.5 percent, is among the lowest figures reported in trials of adjuvant chemotherapy.5,18,26,27
Figures for overall survival at this stage of the study are preliminary, and no conclusion can be drawn about differences in survival between the treatment groups. Since the median overall survival from the time of diagnosis of metastatic colorectal cancer is approximately 20 months,13-15,28 we expect that the effect of oxaliplatin on survival will become apparent within the next 2 years.
Supported by Sanofi-Synthelabo.
Dr. Boni reports having received consulting fees from Sanofi-Synthelabo and Lilly; Dr. Tabernero consulting and lecture fees from Sanofi-Synthelabo; and Dr. Hickish consulting and lecture fees from Sanofi-Synthelabo, Aventis, and Roche. Dr. Topham reports having equity ownership in Sanofi-Synthelabo and having received lecture fees from Sanofi-Synthelabo and consulting fees from Roche and Baxter. Dr. Bridgewater reports having received consulting fees from Novartis Consumer Health; Dr. Clingan consulting fees from Sanofi-Synthelabo and Roche Australia; and Dr. de Gramont consulting and lecture fees from Sanofi-Synthelabo and Baxter. Dr. Mounedji-Boudiaf and Dr. Tabah-Fisch are employed by Sanofi-Synthelabo.
We are indebted to all those who have contributed to the conduct and analysis of the MOSAIC trial, including the 146 investigators from France, the United Kingdom, Spain, Italy, Belgium, Greece, Hungary, the Netherlands, Portugal, Germany, Sweden, Austria, Poland, Denmark, Norway, Australia, Israel, Cyprus, Singapore, and Switzerland who enrolled patients in the study; to the members of the data and safety monitoring board, especially Marc Buyse (statistician); to the dedicated teams from Sanofi-Synthelabo, including Christelle Lorenzato and Robert Bigelow (statistical department) and Jeanne Marceau-Suissa, Nathalie Lebail, and Noelle Muller (clinical development); and to Daniel Sargent (Mayo Clinic) for the discussion of the results.
Source Information
From Hôpital Tenon, Paris (T.A.); GERCOR Oncology Multidisciplinary Group, Paris (T.A., A.G.); Arcispedale Santa Maria Nuova, Reggio Emilia, Italy (C.B.); Sanofi-Synthelabo, Paris (L.M.-B., I.T.-F.); Hospital Duran i Reynals, l'Hospitalet de Llobregat, Llobregat, Spain (M.N.); Vall d'Hebron University Hospital, Barcelona, Spain (J.T.); Dorset Cancer Centre, Royal Bournemouth and Poole Hospitals, Bournemouth, United Kingdom (T.H.); Royal Surrey County Hospital, Guildford, Surrey, United Kingdom (C.T.); Ospedale Borgotrento, Verona, Italy (M.Z.); Southern Medical Day Care Centre, Wollongong, Australia (P.C.); North Middlesex Hospital, London (J.B.); and Hôpital Saint-Antoine, Paris (A.G.).
Address reprint requests to Dr. de Gramont at Hôpital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris 75012, France, or at aimery.de-gramont@sat.ap-hop-paris.fr.
- References
References
1
GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase no. 5. Lyon, France: IARC Press, 2001.
2
Obrand DI ,Gordon PH . Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997;40:15-24
CrossRef | Web of Science | Medline3
Colon and rectum. In: American Joint Committee on Cancer. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott–Raven, 1997:83-90.
4
Moertel CG ,Fleming TR ,Macdonald JS , et al. Levamisole and fluorouracil as adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-358
Full Text | Web of Science | Medline5
Wolmark N ,Rockette H ,Fisher B , et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879-1887
Web of Science | Medline6
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators
CrossRef | Web of Science | Medline7
O'Connell MJ ,Mailliard JA ,Kahn MJ , et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246-250
Web of Science | Medline8
Wolmark N ,Rockette H ,Mamounas E , et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999;17:3553-3559
Web of Science | Medline9
O'Connell MJ ,Laurie JA ,Kahn M , et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16:295-300
Web of Science | Medline10
Haller DG ,Catalano PJ ,Macdonald JS ,Mayer RJ . Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089. Prog Proc Am Soc Clin Oncol 1998;17:256a-256a11
Zaniboni A . Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. J Clin Oncol 1997;15:2432-2441
Web of Science | Medline12
Andre T ,Bensmaine MA ,Louvet C , et al. Multicenter phase II study of bimonthly high-dose leucovorin fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-3568
Web of Science | Medline13
Giacchetti S ,Perpoint B ,Zidani R , et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147
Web of Science | Medline14
de Gramont A ,Figer A ,Seymour M , et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947
Web of Science | Medline15
Goldberg RM ,Sargent DJ ,Morton RF , et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30
CrossRef | Web of Science | Medline16
Elfenbein GJ . Stem-cell transplantation for high-risk breast cancer. N Engl J Med 2003;349:80-82
Full Text | Web of Science | Medline17
Sargent D, Wieand S, Goldberg R, et al. 3 Year DFS vs. 5 year OS as an endpoint for adjuvant colon cancer studies: data from randomized trials. Rockville, Md.: Food and Drug Administration, November 2003. (Accessed May 10, 2004, at http://www.fda.gov/cder/drug/cancer_endpoints/Sargent/index.htm.)
18
Andre T ,Colin P ,Louvet C , et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003;21:2896-2903
CrossRef | Web of Science | Medline19
Francini G ,Petrioli R ,Lorenzini L , et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994;106:899-906
Web of Science | Medline20
Mamounas E ,Wieand S ,Wolmark N , et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999;17:1349-1355
Web of Science | Medline21
International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators
Web of Science | Medline22
Gill S ,Loprinzi CL ,Sargent DJ , et al. Using a pooled analysis to improve the understanding of adjuvant therapy (AT) benefit for colon cancer (CC). Prog Proc Am Soc Clin Oncol 2003;22:253a-253a23
Buyse M ,Piedbois P . Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001;28:Suppl 1:20-24
CrossRef | Web of Science | Medline24
de Gramont A ,Bosset JF ,Milan C , et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-815
Web of Science | Medline25
Extra JM ,Espie M ,Calvo F ,Ferme C ,Mignot L ,Marty M . Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25:299-303
CrossRef | Web of Science | Medline26
Rothenberg ML ,Meropol NJ ,Poplin EA ,Van Cutsem E ,Wadler S . Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-3807
Web of Science | Medline27
Wolmark N ,Bryant J ,Smith R , et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 1998;90:1810-1816
CrossRef | Web of Science | Medline28
Tournigand C ,Andre T ,Achille E , et al. FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237
CrossRef | Web of Science | Medline
- Citing Articles (602)
Citing Articles
1
Fabio Cianchi, Camillo Cortesini, Giacomo Trallori, Luca Messerini, Luca Novelli, Camilla Eva Comin, Etleva Qirici, Andrea Bonanomi, Giuseppe Macrì, Benedetta Badii, Aurora Kokomani, Giuliano Perigli. (2012) Adequacy of Lymphadenectomy in Laparoscopic Colorectal Cancer Surgery. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 22:1, 33-37
CrossRef2
H. K. Sanoff, W. R. Carpenter, C. F. Martin, D. J. Sargent, J. A. Meyerhardt, T. Sturmer, J. P. Fine, J. Weeks, J. Niland, K. L. Kahn, M. J. Schymura, D. Schrag. (2012) Comparative Effectiveness of Oxaliplatin vs Non-Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer. JNCI Journal of the National Cancer Institute
CrossRef3
D. Arnold. (2012) Capecitabin plus Oxaliplatin verglichen mit Fluorouracil und Folinsäure als adjuvante Therapie bei Kolonkarzinom im Stadium III. Strahlentherapie und Onkologie
CrossRef4
I. L. G. Farias, M. C. S. Araújo, J. G. Farias, L. V. Rossato, L. I. Elsenbach, S. L. Dalmora, N. M. P. Flores, M. Durigon, I. B. M. Cruz, V. M. Morsch, M. R. C. Schetinger. (2012) Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial. Evidence-Based Complementary and Alternative Medicine 2012, 1-8
CrossRef5
Jia Li, Michal G. Rose, Melissa F. Perkal, Herta H. Chao. (2012) Pathologic Complete Response After FOLFOX7 in a Locally Advanced Rectal Cancer. Journal of Clinical Gastroenterology 46:1, 87-88
CrossRef6
Janet S Graham, James Cassidy. (2012) Adjuvant therapy in colon cancer. Expert Review of Anticancer Therapy 12:1, 99-109
CrossRef7
Alexander Stein, Dirk Arnold. (2012) Oxaliplatin : a review of approved uses. Expert Opinion on Pharmacotherapy 13:1, 125-137
CrossRef8
Hanna K. Sanoff, William R. Carpenter, Janet Freburger, Ling Li, Kun Chen, Leah L. Zullig, Richard M. Goldberg, Maria J. Schymura, Deborah Schrag. (2012) Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer. Cancern/a-n/a
CrossRef9
Dirk Arnold, Alexander Stein. (2012) Personalized Treatment of Colorectal Cancer. Onkologie 35:s1, 42-48
CrossRef10
Toshikazu Moriwaki, Hideaki Bando, Atsuo Takashima, Kentaro Yamazaki, Taito Esaki, Keishi Yamashita, Mutsumi Fukunaga, Yasuhiro Miyake, Kenji Katsumata, Satoshi Kato, Taroh Satoh, Mitsuharu Ozeki, Eishi Baba, Shigemasa Yoshida, Narikazu Boku, Ichinosuke Hyodo. (2011) Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Medical Oncology
CrossRef11
Natsuko T. Okita, Taito Esaki, Eishi Baba, Daisuke Sakai, Shinya Tokunaga, Hiroya Takiuchi, Nobuyuki Mizunuma, Kengo Nagashima, Ken Kato. (2011) A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer. Investigational New Drugs
CrossRef12
David M. Nagorney, Axel Grothey. (2011) Adjuvant Hepatic Arterial Infusional Chemotherapy. Annals of Surgery 254:6, 857-859
CrossRef13
Aimery de Gramont, Armand de Gramont, Benoist Chibaudel, Annette K. Larsen, Christophe Tournigand, Thierry André. (2011) The Evolution of Adjuvant Therapy in the Treatment of Early-Stage Colon Cancer. Clinical Colorectal Cancer 10:4, 218-226
CrossRef14
Paulo M. Hoff, Everardo D. Saad, Frederico Costa, Anelisa K. Coutinho, Ricardo Caponero, Gabriel Prolla, Rene C. Gansl. (2011) Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity. Clinical Colorectal Cancer
CrossRef15
Takeru Shiroiwa, Toshihiro Takeuchi, Takashi Fukuda, Kojiro Shimozuma, Yasuo Ohashi. (2011) Cost-Effectiveness of Adjuvant FOLFOX Therapy for Stage III Colon Cancer in Japan Based on the MOSAIC Trial. Value in Health
CrossRef16
Mircea Chirica, Mahaut Leconte, Olivier Oberlin, Bertrand Dousset. (2011) Cancers colorectaux : traitement chirurgical des métastases hépatiques. La Presse Médicale
CrossRef17
Chantal W. M. van Gils, Miriam Koopman, Linda Mol, William K. Redekop, Carin A. Uyl-de Groot, Cornelis J. A. Punt. (2011) Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands. Acta Oncologica1-8
CrossRef18
Maya V. Gulubova, Julian R. Ananiev, Tatyana I. Vlaykova, Yovcho Yovchev, Vanya Tsoneva, Irena M. Manolova. (2011) Role of dendritic cells in progression and clinical outcome of colon cancer. International Journal of Colorectal Disease
CrossRef19
N. Cézé, G. Thibault, G. Goujon, J. Viguier, H. Watier, E. Dorval, T. Lecomte. (2011) Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemotherapy and Pharmacology 68:5, 1305-1313
CrossRef20
Sung Pil Hong, Byung So Min, Tae Il Kim, Jae Hee Cheon, Nam Kyu Kim, Hoguen Kim, Won Ho Kim. (2011) The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. European Journal of Cancer
CrossRef21
Mitsugu Kochi, Wataru Ichikawa, Eiji Meguro, Hiroyuki Shibata, Takuji Fukui, Michitaka Nagase, Yutaka Hoshino, Masahiro Takeuchi, Masashi Fujii, Toshifusa Nakajima. (2011) Phase II study of FOLFOX4 with “wait and go” strategy as first-line treatment for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology 68:5, 1215-1222
CrossRef22
Y. Liu, Z. Lu, P. Fan, Q. Duan, Y. Li, S. Tong, B. Hu, R. Lv, L. Hu, J. Zhuang. (2011) Clinical Efficacy of Chemotherapy Combined with Verapamil in Metastatic Colorectal Patients. Cell Biochemistry and Biophysics 61:2, 393-398
CrossRef23
Kenichi Sugihara, Atsushi Ohtsu, Yasuhiro Shimada, Nobuyuki Mizunuma, Po-Huang Lee, Aimery de Gramont, Richard M. Goldberg, Mace L. Rothenberg, Thierry André, Silvano Brienza, Katsushige Gomi. (2011) Safety Analysis of FOLFOX4 Treatment in Colorectal Cancer Patients: A Comparison Between Two Asian Studies and Four Western Studies. Clinical Colorectal Cancer
CrossRef24
José María Vieitez, Rocío García-Carbonero, Jorge Aparicio, Jaime Feliu, Encarnación González-Flores, Enrique Grande, Teresa Pérez-Hoyos, Antonieta Salud, Esperanza Torres, María Valero, Manuel Valladares-Ayerbes, Eduardo Díaz-Rubio. (2011) Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain. Clinical and Translational Oncology 13:11, 798-804
CrossRef25
Anouk Esch, Romain Coriat, Géraldine Perkins, Catherine Brezault, Stanislas Chaussade. (2011) Existe-t-il une alternative à la chimiothérapie adjuvante par FOLFOX dans les cancers coliques de stade III ?. La Presse Médicale
CrossRef26
E. J. Th. Belt, E. A. te Velde, O. Krijgsman, R. P. M. Brosens, M. Tijssen, H. F. Essen, H. B. A. C. Stockmann, H. Bril, B. Carvalho, B. Ylstra, H. J. Bonjer, G. A. Meijer. (2011) High Lymph Node Yield is Related to Microsatellite Instability in Colon Cancer. Annals of Surgical Oncology
CrossRef27
Lars Henrik Jensen, Hidekazu Kuramochi, Dorthe Gylling Crüger, Jan Lindebjerg, Steen Kolvraa, Peter Danenberg, Kathleen Danenberg, Anders Jakobsen. (2011) Gene expression of the mismatch repair gene MSH2 in primary colorectal cancer. Tumor Biology 32:5, 977-983
CrossRef28
Manabu Shimomura, Satoshi Ikeda, Yuji Takakura, Yasuo Kawaguchi, Masakazu Tokunaga, Hiroyuki Egi, Takao Hinoi, Masazumi Okajima, Hideki Ohdan. (2011) Adequate lymph node examination is essential to ensure the prognostic value of the lymph node ratio in patients with stage III colorectal cancer. Surgery Today 41:10, 1370-1379
CrossRef29
Wen-Sy Tsai, Pao-Shiu Hsieh, Chien-Yuh Yeh, Jy-Ming Chiang, Reiping Tang, Jinn-Shiun Chen, Chung Rong Changchien, Jeng Yi Wang. (2011) Long-term survival benefits of adjuvant chemotherapy by decreasing incidence of tumor recurrence without delaying relapse in stage III colorectal cancer. International Journal of Colorectal Disease 26:10, 1329-1338
CrossRef30
Alexander Stein, Sonja Hiemer, Hans-Joachim Schmoll. (2011) Adjuvant Therapy for Early Colon Cancer. Drugs1
CrossRef31
Bruce D. Minsky. (2011) Progress in the Treatment of Locally Advanced Clinically Resectable Rectal Cancer. Clinical Colorectal Cancer
CrossRef32
Joseph C. Murray, Christina S. Wu, Louis M. Weiner. (2011) Why Cetuximab is Not Active in the Adjuvant Setting. Current Colorectal Cancer Reports 7:3, 211-217
CrossRef33
Joleen Hubbard, Axel Grothey. (2011) Reduced Chemotherapy Duration: A Good Idea?. Current Colorectal Cancer Reports 7:3, 241-245
CrossRef34
Tetsuya Homma, Masatsugu Kurokawa, Yoshitaka Yamamoto, Satoshi Matsukura, Koushi Ieki, Shintaro Suzuki, Miho Odaka, Shin Watanabe, Munehiro Yamaguchi, Mitsuru Adachi. (2011) Oxaliplatin-induced lung injury with allergic reaction. Chinese Journal of Cancer Research 23:3, 232-235
CrossRef35
Kathryn M. Field, John R. Zalcberg. (2011) Biological Markers in Patients with Early-Stage Colon Cancer: Consensus and Controversies. Current Colorectal Cancer Reports 7:3, 227-240
CrossRef36
Andreas A. Argyriou, Jordi Bruna, Paola Marmiroli, Guido Cavaletti. (2011) Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Critical Reviews in Oncology/Hematology
CrossRef37
Glauco Baiocchi, Lourival Augusto Cestari, Mariana Petaccia Macedo, Renato Almeida Rosa Oliveira, Elza Mieko Fukazawa, Carlos Chaves Faloppa, Lillian Yuri Kumagai, Levon Badiglian-Filho, Ademir Narciso Oliveira Menezes, Isabela Werneck Cunha, Fernando Augusto Soares. (2011) Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection. Journal of Surgical Oncology 104:3, 250-254
CrossRef38
Rachel P. Riechelmann, Paulo M. Hoff, Fernanda Capareli-Azevedo, Aimery Gramont. (2011) Is There a Future for Bevacizumab in the Adjuvant Setting After the C-08 and AVANT Trials?. Current Colorectal Cancer Reports 7:3, 246-251
CrossRef39
Arvind Dasari, Wells A. Messersmith. (2011) Should We Perform a New Adjuvant Trial with Bevacizumab?. Current Colorectal Cancer Reports 7:3, 218-226
CrossRef40
Hiroshi Katoh, Keishi Yamashita, Guoqin Wang, Takeo Sato, Takatoshi Nakamura, Masahiko Watanabe. (2011) Prognostic Significance of Preoperative Bowel Obstruction in Stage III Colorectal Cancer. Annals of Surgical Oncology 18:9, 2432-2441
CrossRef41
Ya-Hsu Yang, Jen-Kou Lin, Wei-Shone Chen, Tzu-Chen Lin, Shung-Haur Yang, Jeng-Kai Jiang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Chueh-Chuan Yen, Cheng-Hwai Tzeng, Wei-Shu Wang, Huey-Ling Chiang, Chung-Jen Teng, Hao-Wei Teng. (2011) Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Supportive Care in Cancer
CrossRef42
H. J. Chang, K.- W. Lee, J. H. Kim, S. M. Bang, Y. J. Kim, D. W. Kim, S. B. Kang, J. S. Lee. (2011) Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer. Annals of Oncology
CrossRef43
Masanori Nishioka, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Shinya Morimoto, Kozo Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Toru Kono. (2011) The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. International Journal of Clinical Oncology 16:4, 322-327
CrossRef44
Skye C. Mayo, Jennifer E. Heckman, Andrew D. Shore, Hari Nathan, Alexander A. Parikh, John F.P. Bridges, Robert A. Anders, Daniel A. Anaya, Natasha S. Becker, Timothy M. Pawlik. (2011) Shifting trends in liver-directed management of patients with colorectal liver metastasis: A population-based analysis. Surgery 150:2, 204-216
CrossRef45
Cathy J. Bradley, Iris Lansdorp-Vogelaar, K. Robin Yabroff, Bassam Dahman, Angela Mariotto, Eric J. Feuer, Martin L. Brown. (2011) Productivity Savings from Colorectal Cancer Prevention and Control Strategies. American Journal of Preventive Medicine 41:2, e5-e14
CrossRef46
Francesca Pica, Emanuela Balestrieri, Annalucia Serafino, Roberta Sorrentino, Roberta Gaziano, Gabriella Moroni, Noemi Moroni, Graziana Palmieri, Maurizio Mattei, Enrico Garaci, Paola Sinibaldi-Vallebona. (2011) Antitumor effects of the benzophenanthridine alkaloid sanguinarine in a rat syngeneic model of colorectal cancer. Anti-Cancer Drugs1
CrossRef47
Aimery de Gramont, Armand de Gramont, Benoist Chibaudel, Jean-Baptiste Bachet, Annette K. Larsen, Christophe Tournigand, Christophe Louvet, Thierry André. (2011) From Chemotherapy to Targeted Therapy in Adjuvant Treatment for Stage III Colon Cancer. Seminars in Oncology 38:4, 521-532
CrossRef48
Efrat Dotan, Steven J. Cohen. (2011) Challenges in the Management of Stage II Colon Cancer. Seminars in Oncology 38:4, 511-520
CrossRef49
Bruce D. Minsky. (2011) Unique Considerations in the Patient With Rectal Cancer. Seminars in Oncology 38:4, 542-551
CrossRef50
Fei-Yuan Hsiao, C. Daniel Mullins, Ebere Onukwugha, Naimish Pandya, Nader Hanna. (2011) Comparative Effectiveness of Different Chemotherapeutic Regimens on Survival of People Aged 66 and Older with Stage III Colon Cancer: A “Real World” Analysis Using Surveillance, Epidemiology, and End Results-Medicare Data. Journal of the American Geriatrics Societyno-no
CrossRef51
Dawid Murawa, Piotr Nowaczyk, Michael Hünerbein, Karol Połom, Violetta Filas, Jan Bręborowicz, Paweł Murawa. (2011) One hundred consecutive cases of sentinel lymph node mapping in colon cancer—the results of prospective, single-centre feasibility study with implementation of immunohistochemical staining. International Journal of Colorectal Disease 26:7, 897-902
CrossRef52
Anke M. Leufkens, Maurice A.A.J. van den, Maarten S. van Leeuwen, Peter D. Siersema. (2011) Diagnostic accuracy of computed tomography for colon cancer staging: A systematic review. Scandinavian Journal of Gastroenterology 46:7-8, 887-894
CrossRef53
Romina Nassini, Maarten Gees, Selena Harrison, Gaetano De Siena, Serena Materazzi, Nadia Moretto, Paola Failli, Delia Preti, Nicola Marchetti, Alberto Cavazzini, Francesca Mancini, Pamela Pedretti, Bernd Nilius, Riccardo Patacchini, Pierangelo Geppetti. (2011) Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. PAIN 152:7, 1621-1631
CrossRef54
Elizabeth B. Lamont, Mary Beth Landrum, Nancy L. Keating, Samuel R. Bozeman, Barbara J. McNeil. (2011) Evaluating colorectal cancer care in the Veterans Health Administration: How good are the data?. Journal of Geriatric Oncology 2:3, 187-193
CrossRef55
Harunobu Sato, Koutarou Maeda, Kenichi Sugihara, Hidetaka Mochizuki, Kenjiro Kotake, Tetsuo Teramoto, Shingo Kameoka, Yukio Saito, Keiichi Takahashi, Takashi Hirai, Masayuki Ohue, Kazuo Shirouzu, Yoshiharu Sakai, Toshiaki Watanabe, Koichi Hirata, Katsuyoshi Hatakeyama. (2011) High-risk stage II colon cancer after curative resection. Journal of Surgical Oncology 104:1, 45-52
CrossRef56
Minsig Choi, Barbara Craft, Stephen A. Geraci. (2011) Surveillance and Monitoring of Adult Cancer Survivors. The American Journal of Medicine 124:7, 598-601
CrossRef57
Brian G. Czito, Christopher G. Willett. (2011) Beyond 5-Fluorouracil: The Emerging Role of Newer Chemotherapeutics and Targeted Agents with Radiation Therapy. Seminars in Radiation Oncology 21:3, 203-211
CrossRef58
Katherine Van Loon, Alan P Venook. (2011) Adjuvant treatment of colon cancer: what is next?. Current Opinion in Oncology 23:4, 403-409
CrossRef59
Eliza A. Hawkes, David Cunningham, Diana Tait, Gina Brown, Ian Chau. (2011) Neoadjuvant Chemotherapy Alone for Early-Stage Rectal Cancer: An Evolving Paradigm?. Seminars in Radiation Oncology 21:3, 196-202
CrossRef60
, Hirotoshi Kobayashi, Hidetaka Mochizuki, Tomoyuki Kato, Takeo Mori, Shingo Kameoka, Kazuo Shirouzu, Yukio Saito, Masahiko Watanabe, Takayuki Morita, Jin-ichi Hida, Masashi Ueno, Masato Ono, Masamichi Yasuno, Kenichi Sugihara. (2011) Lymph node ratio is a powerful prognostic index in patients with stage III distal rectal cancer: a Japanese multicenter study. International Journal of Colorectal Disease 26:7, 891-896
CrossRef61
Yan Zhang, Jia Yuan, Hong Yan Zhang, Dilixia Simayi, Pin Dong Li, Ying Hong Wang, Feng Li, Wen Jie Zhang. (2011) Natural resistance to apoptosis correlates with resistance to chemotherapy in colorectal cancer cells. Clinical and Experimental Medicine
CrossRef62
Christin Schulze, Margit McGowan, Sven-Eric Jordt, Barbara E. Ehrlich. (2011) Prolonged Oxaliplatin Exposure Alters Intracellular Calcium Signaling: A New Mechanism to Explain Oxaliplatin-Associated Peripheral Neuropathy. Clinical Colorectal Cancer 10:2, 126-133
CrossRef63
D.J. Jonker, K. Spithoff, J. Maroun. (2011) Adjuvant Systemic Chemotherapy for Stage II and III Colon Cancer after Complete Resection: An Updated Practice Guideline. Clinical Oncology 23:5, 314-322
CrossRef64
Martijn HGM van der Pas, Sybren Meijer, Otto S Hoekstra, Ingid I Riphagen, Henrica CW de Vet, Dirk L Knol, Nicole CT van Grieken, Wilhelmus JHJ Meijerink. (2011) Sentinel-lymph-node procedure in colon and rectal cancer: a systematic review and meta-analysis. The Lancet Oncology 12:6, 540-550
CrossRef65
Margaret A. O'Grady, Elyse Slater, Elin R. Sigurdson, Neal J. Meropol, Alan Weinstein, Charles J. Lusch, Elaine Sein, Patricia Keeley, Bonnie Miller, Paul F. Engstrom, Steven J. Cohen. (2011) Assessing Compliance with National Comprehensive Cancer Network Guidelines for Elderly Patients with Stage III Colon Cancer: The Fox Chase Cancer Center Partners' Initiative. Clinical Colorectal Cancer 10:2, 113-116
CrossRef66
Aziz Zaanan, Katy Meunier, Fatiha Sangar, Jean-François Fléjou, Françoise Praz. (2011) Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications. Cellular Oncology 34:3, 155-176
CrossRef67
Ben George, Scott Kopetz. (2011) Predictive and Prognostic Markers in Colorectal Cancer. Current Oncology Reports 13:3, 206-215
CrossRef68
Robin K. Kelley, Alan P. Venook. (2011) Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?. Clinical Colorectal Cancer 10:2, 73-80
CrossRef69
Sergio Afonso, Gustavo Viani, Vitor Afonso, Eduardo Stefano, Sandra Afonso. (2011) Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer. Anti-Cancer Drugs 22, S21-S23
CrossRef70
Ibrahim Aldoss, Syma Iqbal. (2011) Adjuvant Treatment and Predictors of Response in Colon Cancer. Seminars in Colon and Rectal Surgery 22:2, 131-136
CrossRef71
G. Resch, J. Thaler. (2011) Adjuvant chemotherapy in colon carcinoma stages II and III. memo - Magazine of European Medical Oncology 4:2, 86-89
CrossRef72
Yasuhiro Kidera, Taroh Satoh, Shinya Ueda, Wataru Okamoto, Isamu Okamoto, Soichi Fumita, Kimio Yonesaka, Hidetoshi Hayashi, Chihiro Makimura, Kunio Okamoto, Hidemi Kiyota, Junji Tsurutani, Masaki Miyazaki, Masahiro Yoshinaga, Kimiko Fujiwara, Yuzuru Yamazoe, Kenzo Moriyama, Masanobu Tsubaki, Yasutaka Chiba, Shozo Nishida, Kazuhiko Nakagawa. (2011) High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. International Journal of Clinical Oncology 16:3, 244-249
CrossRef73
M. Thorsteinsson, P. Jess. (2011) The clinical significance of circulating tumor cells in non-metastatic colorectal cancer – A review. European Journal of Surgical Oncology (EJSO) 37:6, 459-465
CrossRef74
Mitsukuni SUENAGA, Satoshi MATSUSAKA, Toshiyasu WATANABE, Yasutoshi KUBOKI, Eiji SHINOZAKI, Keisho CHIN, Nobuyuki MIZUNUMA, Masashi UENO, Toshiharu YAMAGUCHI, Kiyohiko HATAKE. (2011) How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer?. Asia-Pacific Journal of Clinical Oncology 7:2, 129-135
CrossRef75
Hagen Kennecke, Scott Berry, Ralph Wong, Chen Zhou, Keith Tankel, Jacob Easaw, Sanjay Rao, Jacqueline Post, John Hay. (2011) Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: A phase II trial. European Journal of Cancer
CrossRef76
Satoshi Ishizone, Naohiko Koide, Noriyuki Akita, Fumitoshi Karasawa, Nobumitsu Kobayashi, Tomonobu Koizumi, Shinichi Miyagawa. (2011) Fatal interstitial pneumonia associated with oxaliplatin-based therapy in a patient with metastatic rectal cancer. Clinical Journal of Gastroenterology 4:3, 157-161
CrossRef77
Terence C. Chua, Winston Liauw, Heng-Nung Koong, Jesus Esquivel. (2011) Surgical Therapies in Metastatic Colorectal Cancer With a Potential for Cure. American Journal of Clinical Oncology 34:3, 326-331
CrossRef78
Hui Zheng, Wei Zhang, John Z. Ayanian, Lawrence B. Zaborski, Alan M. Zaslavsky. (2011) Profiling Hospitals by Survival of Patients with Colorectal Cancer. Health Services Research 46:3, 729-746
CrossRef79
Lakshmi Chintala, Susmitha Vaka, Joaquina Baranda, Stephen K. Williamson. (2011) Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?. Oncology Reviews 5:2, 129-140
CrossRef80
Robert Glynne-Jones, Miranda Kronfli. (2011) Locally Advanced Rectal Cancer. Drugs 71:9, 1153-1177
CrossRef81
Ulas Darda Bayraktar, Emerson Chen, Soley Bayraktar, Laurence R. Sands, Floriano Marchetti, Alberto Jose Montero, Caio Max S. Rocha-Lima. (2011) Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma?. Cancer 117:11, 2364-2370
CrossRef82
Paul L MITCHELL, Adam BROAD, Mark A ROSENTHAL, Peter GALETTIS, Rick ABRAHAM, Ivon BURNS, Stephen CLARKE, Alvin MILNER, Juliana DIIULIO, Matthew LINKS. (2011) Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncologyno-no
CrossRef83
U Wallin, B Glimelius, K Jirström, S Darmanis, R Y Nong, F Pontén, C Johansson, L Påhlman, H Birgisson. (2011) Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. British Journal of Cancer 104:10, 1619-1627
CrossRef84
Juliette Descoeur, Vanessa Pereira, Anne Pizzoccaro, Amaury Francois, Bing Ling, Violette Maffre, Brigitte Couette, Jérôme Busserolles, Christine Courteix, Jacques Noel, Michel Lazdunski, Alain Eschalier, Nicolas Authier, Emmanuel Bourinet. (2011) Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Molecular Medicine 3:5, 266-278
CrossRef85
Roel Hompes, Chris Cunningham. (2011) Colorectal cancer: management. Medicine 39:5, 254-258
CrossRef86
D. Sargent, Q. Shi, G. Yothers, E. Van Cutsem, J. Cassidy, L. Saltz, N. Wolmark, B. Bot, A. Grothey, M. Buyse, A. de Gramont. (2011) Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. European Journal of Cancer 47:7, 990-996
CrossRef87
Michael Jefford, Kerryann Lotfi-Jam, Carl Baravelli, Suzi Grogan, Megan Rogers, Meinir Krishnasamy, Carmel Pezaro, Donna Milne, Sanchia Aranda, Dorothy King, Beryl Shaw, Penelope Schofield. (2011) Development and Pilot Testing of a Nurse-Led Posttreatment Support Package for Bowel Cancer Survivors. Cancer Nursing 34:3, E1-E10
CrossRef88
Stefania Nobili, Cristina Napoli, Ida Landini, Maria Morganti, Fabio Cianchi, Rosa Valanzano, Francesco Tonelli, Camillo Cortesini, Teresita Mazzei, Enrico Mini. (2011) Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. International Journal of Cancer 128:8, 1935-1945
CrossRef89
Shailender Singh Kanwar, Yingjie Yu, Jyoti Nautiyal, Bhaumik B. Patel, Subhash Padhye, Fazlul H. Sarkar, Adhip P. N. Majumdar. (2011) Difluorinated-Curcumin (CDF): A Novel Curcumin Analog is a Potent Inhibitor of Colon Cancer Stem-Like Cells. Pharmaceutical Research 28:4, 827-838
CrossRef90
Campbell Roxburgh, Alec McDonald, Jonathan Salmond, Karin Oien, John Anderson, Ruth McKee, Paul Horgan, Donald McMillan. (2011) Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors. International Journal of Colorectal Disease 26:4, 483-492
CrossRef91
Madhu B. Garg, Stephen P. Ackland. (2011) Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect. Cancer Chemotherapy and Pharmacology 67:4, 963-966
CrossRef92
Daniel V.T. Catenacci, Mark Kozloff, Hedy L. Kindler, Blase Polite. (2011) Personalized Colon Cancer Care in 2010. Seminars in Oncology 38:2, 284-308
CrossRef93
Jinghua Shi, Oguzhan Alagoz, Fatih Safa Erenay, Qiang Su. (2011) A survey of optimization models on cancer chemotherapy treatment planning. Annals of Operations Research
CrossRef94
C-Y Lu, Y-H Uen, H-L Tsai, S-C Chuang, M-F Hou, D-C Wu, S-H Hank Juo, S-R Lin, J-Y Wang. (2011) Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse. British Journal of Cancer 104:7, 1178-1184
CrossRef95
J. P. Durand, G. Deplanque, V. Montheil, J. M. Gornet, F. Scotte, O. Mir, A. Cessot, R. Coriat, E. Raymond, E. Mitry, P. Herait, Y. Yataghene, F. Goldwasser. (2011) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology
CrossRef96
Yung-Sung Yeh, Hwei-Ming Wang, Shiu-Ru Lin, Jaw-Yuan Wang. (2011) Prognostic and Molecular Factors in Stage II Colorectal Cancer. Genomic Medicine, Biomarkers, and Health Sciences 3:1, 2-8
CrossRef97
Autumn J McRee, Stacy Cowherd, Andrew Z Wang, Richard M Goldberg. (2011) Chemoradiation therapy in the management of gastrointestinal malignancies. Future Oncology 7:3, 409-426
CrossRef98
Joseph Sung. (2011) Future role of gastroenterologists in digestive oncology in the Asia Pacific region: Panir Chelvam Memorial Lecture, Asian Pacific Digestive Week 2010. Journal of Gastroenterology and Hepatology 26:3, 432-436
CrossRef99
Karen Mulder, Andrew Scarfe, Neil Chua, Jennifer Spratlin. (2011) The role of bevacizumab in colorectal cancer: understanding its benefits and limitations. Expert Opinion on Biological Therapy 11:3, 405-413
CrossRef100
Timothy M. Pawlik, David Cosgrove. (2011) The Role of Peri-operative Chemotherapy for Resectable Colorectal Liver Metastasis: What Does the Evidence Support?. Journal of Gastrointestinal Surgery 15:3, 410-415
CrossRef101
Dennis A. Wicherts, Robbert J. Haas, Mylène Sebagh, Oriana Ciacio, Francis Lévi, Bernard Paule, Sylvie Giacchetti, Catherine Guettier, Daniel Azoulay, Denis Castaing, René Adam. (2011) Regenerative Nodular Hyperplasia of the Liver Related to Chemotherapy: Impact on Outcome of Liver Surgery for Colorectal Metastases. Annals of Surgical Oncology 18:3, 659-669
CrossRef102
Francesco Dionisi, Daniela Musio, Nicola Raffetto, Giovanni Codacci-Pisanelli, Eva Iannacone, Rossella Caiazzo, Enzo Banelli. (2011) Preoperative intensified radiochemotherapy for rectal cancer: experience of a single institution. International Journal of Colorectal Disease 26:2, 153-164
CrossRef103
Colin R Lindsay, Jim Cassidy. (2011) XELOX in colorectal cancer: a convenient option for the future?. Expert Review of Gastroenterology & Hepatology 5:1, 9-19
CrossRef104
Claus Lindbjerg Andersen, Philippe Lamy, Kasper Thorsen, Eigil Kjeldsen, Friedrik Wikman, Palle Villesen, Bodil Øster, Søren Laurberg, Torben Falck Ørntoft. (2011) Frequent genomic loss at chr16p13.2 is associated with poor prognosis in colorectal cancer. International Journal of Cancern/a-n/a
CrossRef105
Susanna B. Park, Cindy S.-Y. Lin, Arun V. Krishnan, David Goldstein, Michael L. Friedlander, Matthew C. Kiernan. (2011) Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology 227:1, 120-127
CrossRef106
Hong-Hee Won, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Jong-Won Kim, Soo-Youn Lee, Se Hoon Park. (2011) Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancern/a-n/a
CrossRef107
Hiroshi Katoh, Keishi Yamashita, Guoqin Wang, Takeo Sato, Takatoshi Nakamura, Masahiko Watanabe. (2011) Anastomotic Leakage Contributes to the Risk for Systemic Recurrence in Stage II Colorectal Cancer. Journal of Gastrointestinal Surgery 15:1, 120-129
CrossRef108
Frank Makowiec, Simone Möhrle, Hannes Neeff, Oliver Drognitz, Gerald Illerhaus, Oliver G. Opitz, Ulrich T. Hopt, Axel Hausen. (2011) Chemotherapy, Liver Injury, and Postoperative Complications in Colorectal Liver Metastases. Journal of Gastrointestinal Surgery 15:1, 153-164
CrossRef109
Jyoti Nautiyal, Shailender S Kanwar, Yingjie Yu, Adhip PN Majumdar. (2011) Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. Journal of Molecular Signaling 6:1, 7
CrossRef110
Daniel J Lips, Boukje Koebrugge, Gerrit Jan Liefers, Johannes C van de Linden, Vincent THBM Smit, Hans FM Pruijt, Hein Putter, Cornelis JH van de Velde, Koop Bosscha. (2011) The influence of micrometastases on prognosis and survival in stage I-II colon cancer patients: the Enroute
Study. BMC Surgery 11:1, 11
CrossRef111
Ralf Gutzmer, Elke Jäger, Dirk Vordermark. (2011) Adjuvante Therapieansätze in der Onkologie: Eine kritische Nutzen-Risiko-Abwägung. Onkologie 34:s2, 10-12
CrossRef112
Niamh McCawley, Susan Conlon, Suzanne Hector, Robert J. Cummins, Patrick Dicker, Patrick G. Johnston, Elaine W. Kay, Deborah A. McNamara, Jochen H.M. Prehn, Caoimhín G. Concannon. (2011) Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer. International Journal of Cancern/a-n/a
CrossRef113
Wataru Onozato, Keishi Yamashita, Kazuya Yamashita, Tatsuru Kuba, Hiroshi Katoh, Takatoshi Nakamura, Takeo Sato, Atsushi Ihara, Isao Okayasu, Masahiko Watanabe. (2011) Genetic alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60 years of age. Journal of Surgical Oncology 103:1, 25-33
CrossRef114
Andrew K. Chan, Bok A. Choo, John Glaholm. (2011) Pulmonary Toxicity with Oxaliplatin and Capecitabine/5-Fluorouracil Chemotherapy: A Case Report and Review of the Literature. Onkologie 34:8, 443-446
CrossRef115
Hyeong-Joon Jeon, Jin-Hee Woo, Hak-Yoon Lee, Ki-Jae Park, Hong-Jo Choi. (2011) Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer. Journal of the Korean Society of Coloproctology 27:3, 140
CrossRef116
Tamantha K. Stutchbury, Kara L. Vine, Julie M. Locke, Jeremy S. Chrisp, John B. Bremner, Philip R. Clingan, Marie Ranson. (2011) Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles. Anti-Cancer Drugs 22:1, 24-34
CrossRef117
Daniel J. Sargent. (2011) Chemotherapy: Failure of bevacizumab in early-stage colon cancer. Nature Reviews Clinical Oncology 8:1, 10-11
CrossRef118
Christina D. Mack, William Carpenter, Anne-Marie Meyer, Hanna Sanoff, Til Stürmer. (2011) Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults. Cancern/a-n/a
CrossRef119
Natasha M. Rueth, Sara E. Murray, Stephen J. Huddleston, Andrea M. Abbott, Edward W. Greeno, Mark N. Kirstein, Todd M. Tuttle. (2011) Severe Electrolyte Disturbances After Hyperthermic Intraperitoneal Chemotherapy: Oxaliplatin Versus Mitomycin C. Annals of Surgical Oncology 18:1, 174-180
CrossRef120
Chun-Geun Ryu, Eun-Joo Jung, Gangmi Kim, Su Ran Kim, Dae-Yong Hwang. (2011) Oxaliplatin-induced Pulmonary Fibrosis: Two Case Reports. Journal of the Korean Society of Coloproctology 27:5, 266
CrossRef121
Michiki NARUSHIMA, Yoshihito OHTA, Adoru OKAUE, Makoto URANO. (2011) A CASE OF PANCREATIC METASTATIS EIGHT YEARS AFTER SURGERY FOR SIGMOID COLON CANCER. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 72:5, 1207-1212
CrossRef122
Andrew Weickhardt, Keith Wells, Wells Messersmith. (2011) Oxaliplatin-Induced Neuropathy in Colorectal Cancer. Journal of Oncology 2011, 1-7
CrossRef123
Nabil Ismaili. (2011) Treatment of colorectal liver metastases. World Journal of Surgical Oncology 9:1, 154
CrossRef124
Sun Hee Jee, Sun Mi Moon, Ui Sup Shin, Hoe Min Yang, Dae-Yong Hwang. (2011) Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer. Journal of the Korean Society of Coloproctology 27:6, 322
CrossRef125
Raghib Ali, Han-Chong Toh, Whay-Kuang Chia. (2011) The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer - The ASCOLT study: Study Protocol for a randomized controlled trial. Trials 12:1, 261
CrossRef126
Alan A. Thomay, Kevin P. Charpentier. (2010) Optimizing resection for “responding” hepatic metastases after neoadjuvant chemotherapy. Journal of Surgical Oncology 102:8, 1002-1008
CrossRef127
Harold J. Wanebo, David Berz. (2010) The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors. Journal of Surgical Oncology 102:8, 891-897
CrossRef128
R K Van Laar. (2010) An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. British Journal of Cancer 103:12, 1852-1857
CrossRef129
Wen-Yee CHAY, Sze-Huey TAN, Yew-Long LO, Simon Yew-Kwang ONG, Hui-Cheng NG, Fei GAO, Wen-Hsin KOO, Su-Pin CHOO. (2010) Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia-Pacific Journal of Clinical Oncology 6:4, 270-277
CrossRef130
N. Jacobi, F. Gieseler. (2010) Adjuvant and neoadjuvant therapy in colorectal cancer. European Surgery 42:6, 283-286
CrossRef131
Angela Hyde, Daniel Fontaine, Susan Stuckless, Roger Green, Aaron Pollett, Michelle Simms, Payal Sipahimalani, Patrick Parfrey, Banfield Younghusband. (2010) A Histology-Based Model for Predicting Microsatellite Instability in Colorectal Cancers. The American Journal of Surgical Pathology 34:12, 1820-1829
CrossRef132
Laura Rubbia-Brandt. (2010) Lésions hépatiques induites par la chimiothérapie systémique pour cancer d’origine digestive. Annales de Pathologie 30:6, 421-425
CrossRef133
Stefan Madajewicz, David M. Waterhouse, Paul S. Ritch, M. Qaseem Khan, Donald J. Higby, Cynthia G. Leichman, Sandeep K. Malik, Patricia Hentschel, John F. Gill, Luping Zhao, Steven J. Nicol. (2010) Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. Investigational New Drugs
CrossRef134
Takatoshi Matsuyama, Toshiaki Ishikawa, Kaoru Mogushi, Tsuyoshi Yoshida, Satoru Iida, Hiroyuki Uetake, Hiroshi Mizushima, Hiroshi Tanaka, Kenichi Sugihara. (2010) MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer. International Journal of Cancer 127:10, 2292-2299
CrossRef135
Laura Rubbia-Brandt. (2010) Sinusoidal Obstruction Syndrome. Clinics in Liver Disease 14:4, 651-668
CrossRef136
N. Silvestris, E. Maiello, F. De Vita, S. Cinieri, D. Santini, A. Russo, S. Tommasi, A. Azzariti, G. Numico, S. Pisconti, D. Petriella, V. Lorusso, A. Millaku, G. Colucci. (2010) Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treatment Reviews 36, S46-S55
CrossRef137
T Conroy, Y Yataghène, P L Etienne, P Michel, H Senellart, J L Raoul, L Mineur, M Rives, X Mirabel, B Lamezec, E Rio, E Le Prisé, D Peiffert, A Adenis. (2010) Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. British Journal of Cancer 103:9, 1349-1355
CrossRef138
C.S. Boskos, C. Liacos, D. Korkolis, K. Aygerinos, I. Lamproglou, E. Terpos, E. Stoupa, G. Baltatzis, K. Beroukas, P. Papasavvas, M.A. Dimopoulos, A. Bamias. (2010) Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer. Journal of Surgical Oncology 102:5, 408-412
CrossRef139
Matthew W. Bending, Paul Trueman, Karin V. Lowson, Hazel Pilgrim, Paul Tappenden, Jim Chilcott, Janine Tappenden. (2010) Estimating the direct costs of bowel cancer services provided by the National Health Service in England. International Journal of Technology Assessment in Health Care 26:04, 362-369
CrossRef140
Rui Zhang, Jing Zhu, Sheng Wang, Lixia Ma. (2010) Report on the 10 cases of allergic reactions to oxaliplatin. The Chinese-German Journal of Clinical Oncology 9:10, 610-612
CrossRef141
Richard Cathomas, Dieter Köberle, Thomas Ruhstaller, Gisela Mayer, Andrea Räss, Ulrich Mey, Roger Moos. (2010) Heated (37°C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?. Supportive Care in Cancer 18:10, 1263-1270
CrossRef142
A. Lièvre. (2010) Vers un traitement personnalisé du cancer colorectal: facteurs pronostiques et prédictifs. Oncologie 12:10, 584-592
CrossRef143
T. Shimura, N. Fuse, T. Yoshino, K. Minashi, M. Tahara, T. Doi, T. Joh, A. Ohtsu. (2010) Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Annals of Oncology 21:10, 2005-2010
CrossRef144
Tanya M. Wildes, Dorina Kallogjeri, Brian Powers, Anna Vlahiotis, Matthew Mutch, Edward L. Spitznagel, Benjamin Tan, Jay F. Piccirillo. (2010) The benefit of adjuvant chemotherapy in elderly patients with stage III colorectal cancer is independent of age and comorbidity. Journal of Geriatric Oncology 1:2, 48-56
CrossRef145
Leonard B. Saltz. (2010) Adjuvant Therapy for Colon Cancer. Surgical Oncology Clinics of North America 19:4, 819-827
CrossRef146
Bernard Nordlinger, Jean-Nicolas Vauthey, Graeme Poston, Stephane Benoist, Philippe Rougier, Eric Van Cutsem. (2010) The Timing of Chemotherapy and Surgery for the Treatment of Colorectal Liver Metastases. Clinical Colorectal Cancer 9:4, 212-218
CrossRef147
Bruce D. Minsky. (2010) Chemoradiation for Rectal Cancer: Rationale, Approaches, and Controversies. Surgical Oncology Clinics of North America 19:4, 803-818
CrossRef148
Cecilia Guastadisegni, Mauro Colafranceschi, Laura Ottini, Eugenia Dogliotti. (2010) Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data. European Journal of Cancer 46:15, 2788-2798
CrossRef149
Derek G. Power, Emily Gloglowski, Steven M. Lipkin. (2010) Clinical Genetics of Hereditary Colorectal Cancer. Hematology/Oncology Clinics of North America 24:5, 837-859
CrossRef150
Francine Aubin, Charles D. Blanke. (2010) Optimal Adjuvant Therapy for Patients with Resected Rectal Cancers. Current Colorectal Cancer Reports 6:4, 180-182
CrossRef151
John B. Kisiel, Paul J. Limburg. 2010. Colonic Polyps and Colon Cancer. , 351-360.
CrossRef152
Jin Soo Kim, Nam Kyu Kim, Byung Soh Min, Hyuk Hur, Joong Bae Ahn, Ki Chang Keum. (2010) Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: is it beneficial?. International Journal of Colorectal Disease 25:9, 1103-1110
CrossRef153
Cheng E. Chee, Frank A. Sinicrope. (2010) Targeted Therapeutic Agents for Colorectal Cancer. Gastroenterology Clinics of North America 39:3, 601-613
CrossRef154
Halina Frydman, Michael Szarek. (2010) Estimation of overall survival in an ‘illness-death’ model with application to the vertical transmission of HIV-1. Statistics in Medicine 29:19, 2045-2054
CrossRef155
Romain Coriat, Olivier Mir, Anatole Cessot, Catherine Brezault, Stanislas Ropert, Jean-Philippe Durand, Wulfran Cacheux, Stanislas Chaussade, François Goldwasser. (2010) Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. Investigational New Drugs
CrossRef156
D. J. Storey, M. Sakala, C. M. McLean, H. A. Phillips, L. K. Dawson, L. R. Wall, M. T. Fallon, S. Clive. (2010) Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?. Annals of Oncology 21:8, 1657-1661
CrossRef157
Toshiaki Watanabe, Takashi Kobunai, Yoko Yamamoto, Takamitsu Kanazawa, Tsuyoshi Konishi, Toshiaki Tanaka, Keiji Matsuda, Soichiro Ishihara, Keijiro Nozawa, Kiyoshi Eshima, Tetsuichiro Muto, Hirokazu Nagawa. (2010) Prediction of liver metastasis after colorectal cancer using reverse transcription-polymerase chain reaction analysis of 10 genes. European Journal of Cancer 46:11, 2119-2126
CrossRef158
Joleen Hubbard, Axel Grothey. (2010) Strategies for Managing Chemotherapy-Induced Sensory Neuropathy. Current Colorectal Cancer Reports 6:3, 126-132
CrossRef159
Axel Grothey. (2010) Adjuvant chemotherapy in colon cancer – Is it worth it?. European Journal of Cancer 46:10, 1768-1769
CrossRef160
D Cunningham, B Minsky, HJ Lenz, B Nordlinger, N Starling. (2010) Colorectal cancer – Authors' reply. The Lancet 376:9738, 331-332
CrossRef161
Haskell M. Kirkpatrick, Cristi L. Aitelli, Huanying Qin, Carlos Becerra, Warren E. Lichliter, A. David McCollum. (2010) Referral Patterns and Adjuvant Chemotherapy Use in Patients With Stage II Colon Cancer. Clinical Colorectal Cancer 9:3, 150-156
CrossRef162
A. Rajput, D. Romanus, M.R. Weiser, A. Ter Veer, J. Niland, J. Wilson, J.M. Skibber, Y.-N. Wong, A. Benson, C.C. Earle, D. Schrag. (2010) Meeting the 12 lymph node (LN) benchmark in colon cancer. Journal of Surgical Oncology 102:1, 3-9
CrossRef163
A. Astier. (2010) Apports récents de la pharmacogénomique dans le traitement des cancers colorectaux. Annales Pharmaceutiques Françaises 68:4, 233-253
CrossRef164
Jing-Quan Li, Shi-Liang Wang, Fei Xu, Zhao-Yang Liu, Rong Li. (2010) Therapeutic effectiveness of slow-release PLGA-oxaliplatin microsphere on human colorectal tumor-bearing mice. Anti-Cancer Drugs 21:6, 600-608
CrossRef165
Ester J. M. Siemerink, Annemieke F. J. Drenth, Nanno H. Mulder, John T. M. Plukker, Geke A. P. Hospers. (2010) Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer. Gastric Cancer 13:2, 95-100
CrossRef166
Anning Yin, Yingan Jiang, Xianfeng Zhang, Hesheng Luo. (2010) Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. Medical Oncology 27:2, 397-405
CrossRef167
Tara Gangadhar, Richard L. Schilsky. (2010) Molecular markers to individualize adjuvant therapy for colon cancer. Nature Reviews Clinical Oncology 7:6, 318-325
CrossRef168
Tina Ashley Khair, Peter Kozuch. (2010) Minimizing the Therapy-Related Morbidity in the Rectal Cancer Patient. Seminars in Colon and Rectal Surgery 21:2, 120-125
CrossRef169
G. Folprecht. (2010) Aktuelle medikamentöse Therapie des metastasierten Kolonkarzinoms. Der Chirurg 81:6, 507-515
CrossRef170
Yu Katayose, Michiaki Unno. (2010) Management of liver metastases from colorectal cancer. Clinical Journal of Gastroenterology 3:3, 128-135
CrossRef171
Benjamin P. Negin, Steven J. Cohen. (2010) Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future Challenges. Current Treatment Options in Oncology 11:1-2, 1-13
CrossRef172
Jean-Emmanuel Kurtz, Damien Heitz, Sebastian Serra, Cécile Brigand, Vanessa Juif, Valérie Podelski, Pierre Meyer, Valère Litique, Jean-Pierre Bergerat, Serge Rohr, Patrick Dufour. (2010) Adjuvant chemotherapy in elderly patients with colorectal cancer. A retrospective analysis of the implementation of tumor board recommendations in a single institution. Critical Reviews in Oncology/Hematology 74:3, 211-217
CrossRef173
L. N. van Steenbergen, H. J. T. Rutten, G. J. Creemers, J. F. M. Pruijt, J. W. W. Coebergh, V. E. P. P. Lemmens. (2010) Large age and hospital-dependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands. Annals of Oncology 21:6, 1273-1278
CrossRef174
Kazushi Suzuki, Toshio Kokuryo, Takeshi Senga, Yukihiro Yokoyama, Masato Nagino, Michinari Hamaguchi. (2010) Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin. Cancer Science 101:5, 1163-1169
CrossRef175
R. Glynne-Jones. (2010) Whose Guidelines are they Anyway?. Clinical Oncology 22:4, 261-264
CrossRef176
Joleen M. Hubbard, Steven R. Alberts. (2010) Treatment of Liver-Limited Metastatic Colorectal Cancer. The Cancer Journal 16:3, 235-240
CrossRef177
R.K.S. Wong, S. Berry, K. Spithoff, M. Simunovic, K. Chan, O. Agboola, B. Dingle. (2010) Preoperative or Postoperative Therapy for Stage II or III Rectal Cancer: An Updated Practice Guideline. Clinical Oncology 22:4, 265-271
CrossRef178
Roberto Labianca, Giordano D. Beretta, Basem Kildani, Laura Milesi, Federica Merlin, Stefania Mosconi, M. Adelaide Pessi, Tiziana Prochilo, Antonello Quadri, Gemma Gatta, Filippo de Braud, Jacques Wils. (2010) Colon cancer. Critical Reviews in Oncology/Hematology 74:2, 106-133
CrossRef179
R. Labianca, B. Nordlinger, G. D. Beretta, A. Brouquet, A. Cervantes, . (2010) Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Annals of Oncology 21:Supplement 5, v70-v77
CrossRef180
Bruce D. Minsky, Claus Röedel, Vincenzo Valentini. (2010) Combined Modality Therapy for Rectal Cancer. The Cancer Journal 16:3, 253-261
CrossRef181
Benoît Rousseau, Benoist Chibaudel, Jean-Baptiste Bachet, Annette K. Larsen, Christophe Tournigand, Christophe Louvet, Thierry André, Aimery de Gramont. (2010) Stage II and Stage III Colon Cancer. The Cancer Journal 16:3, 202-209
CrossRef182
Michael J. Overman, Scott Kopetz, E. Lin, James L. Abbruzzese, Robert A. Wolff. (2010) Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncologica 49:4, 474-479
CrossRef183
Derek G. Power, Stuart M. Lichtman. (2010) Chemotherapy for the Elderly Patient With Colorectal Cancer. The Cancer Journal 16:3, 241-252
CrossRef184
Carla Kurkjian, Shivaani Kummar. (2010) Advances in the Treatment of Metastatic Colorectal Cancer. Disease-a-Month 56:4, 187-203
CrossRef185
Jennie H Best, Louis P Garrison. (2010) Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer. Expert Review of Pharmacoeconomics & Outcomes Research 10:2, 103-114
CrossRef186
A. Zaanan, P. Cuilliere-Dartigues, A. Guilloux, Y. Parc, C. Louvet, A. de Gramont, E. Tiret, S. Dumont, B. Gayet, P. Validire, J.-F. Flejou, A. Duval, F. Praz. (2010) Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Annals of Oncology 21:4, 772-780
CrossRef187
Simona Potenza, Guglielmo Nasti, Ottaiano Alessandro, Amelia Filippelli, Francesco Rossi, Annalisa Capuano. (2010) Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction. Investigational New Drugs 28:2, 185-186
CrossRef188
Hanna K. Sanoff, Richard M. Goldberg, Michael P. Pignone. (2010) Assessing the Quality of Initial Consultations Regarding Adjuvant Colon Cancer Therapy. Clinical Colorectal Cancer 9:2, 113-118
CrossRef189
Daniel Sargent, Axel Grothey. (2010) Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future. Annals of Surgical Oncology 17:4, 947-949
CrossRef190
R. K. Ramanathan, M. L. Rothenberg, A. de Gramont, C. Tournigand, R. M. Goldberg, S. Gupta, T. Andre. (2010) Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Annals of Oncology 21:4, 754-758
CrossRef191
Masashi Kanai, Akira Yoshioka, Shiro Tanaka, Satoshi Nagayama, Shigemi Matsumoto, Takafumi Nishimura, Miyuki Niimi, Satoshi Teramukai, Ryo Takahashi, Yukiko Mori, Toshiyuki Kitano, Hiroshi Ishiguro, Kazuhiro Yanagihara, Tsutomu Chiba, Masanori Fukushima, Fumihiko Matsuda. (2010) Associations between glutathione S-transferase π Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiology 34:2, 189-193
CrossRef192
Neal W. Wilkinson, Greg Yothers, Samia Lopa, Joseph P. Costantino, Nicholas J. Petrelli, Norman Wolmark. (2010) Long-Term Survival Results of Surgery Alone Versus Surgery Plus 5-Fluorouracil and Leucovorin for Stage II and Stage III Colon Cancer: Pooled Analysis of NSABP C-01 Through C-05. A Baseline from Which to Compare Modern Adjuvant Trials. Annals of Surgical Oncology 17:4, 959-966
CrossRef193
Jennie H. Best, Louis P. Garrison, William Hollingworth, Scott D. Ramsey, David L. Veenstra. (2010) Preference values associated with stage III colon cancer and adjuvant chemotherapy. Quality of Life Research 19:3, 391-400
CrossRef194
John Goffin. 2010. Introduction to Clinical Trials. .
CrossRef195
Tsunekazu Mizushima, Masaya Nomura, Makoto Fujii, Hiroki Akamatsu, Hitoshi Mizuno, Harumi Tominaga, Junichi Hasegawa, Kiyokazu Nakajima, Keigo Yasumasa, Masato Yoshikawa, Toshirou Nishida. (2010) Primary colorectal signet-ring cell carcinoma: Clinicopathological features and postoperative survival. Surgery Today 40:3, 234-238
CrossRef196
Laura Rubbia-Brandt, Gregory Y Lauwers, Huamin Wang, Pietro E Majno, Kenneth Tanabe, Andrew X Zhu, Catherine Brezault, Olivier Soubrane, Eddie K Abdalla, Jean-Nicolas Vauthey, Gilles Mentha, Benoit Terris. (2010) Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56:4, 430-439
CrossRef197
U. Wedding. (2010) Möglichkeiten und Grenzen der onkologischen Chemotherapie bei alten Patienten. Der Internist 51:3, 402-409
CrossRef198
David Cunningham, Wendy Atkin, Heinz-Josef Lenz, Henry T Lynch, Bruce Minsky, Bernard Nordlinger, Naureen Starling. (2010) Colorectal cancer. The Lancet 375:9719, 1030-1047
CrossRef199
R. Velasco, J. Bruna. (2010) Neuropatía inducida por quimioterapia: un problema no resuelto. Neurología 25:2, 116-131
CrossRef200
, Paula Manchon Walsh, Josep M. Borràs, Tàrsila Ferro, Josep Alfons Espinàs. (2010) Colorectal cancer OncoGuia. Clinical and Translational Oncology 12:3, 188-210
CrossRef201
Thorvardur R. Halfdanarson, Michael L. Kendrick, Axel Grothey. (2010) The Role of Chemotherapy in Managing Patients With Resectable Liver Metastases. The Cancer Journal 16:2, 125-131
CrossRef202
R. Velasco, J. Bruna. (2010) Chemotherapy-induced peripheral neuropathy: An unresolved issue. Neurología (English Edition) 25:2, 116-131
CrossRef203
Frédéric Hollande, Julie Pannequin, Dominique Joubert. (2010) The long road to colorectal cancer therapy: Searching for the right signals. Drug Resistance Updates 13:1-2, 44-56
CrossRef204
Hiroshi Sawayama, Naoko Hayashi, Shinobu Honda, Yoshifumi Baba, Eiichirou Toyama, Masayuki Watanabe, Hiroshi Takamori, Toru Beppu, Hideo Baba. (2010) Treatment results of FOLFOX chemotherapy before surgery for lymph node metastasis of advanced colorectal cancer with synchronous liver metastasis: the status of LN metastasis and vessel invasions at the primary site in patients who responded to FOLFOX. International Journal of Clinical Oncology 15:1, 70-76
CrossRef205
Terence C. Chua, Akshat Saxena, Winston Liauw, Adel Kokandi, David L. Morris. (2010) Systematic Review of Randomized and Nonrandomized Trials of the Clinical Response and Outcomes of Neoadjuvant Systemic Chemotherapy for Resectable Colorectal Liver Metastases. Annals of Surgical Oncology 17:2, 492-501
CrossRef206
Brenda K. Edwards, Elizabeth Ward, Betsy A. Kohler, Christie Eheman, Ann G. Zauber, Robert N. Anderson, Ahmedin Jemal, Maria J. Schymura, Iris Lansdorp-Vogelaar, Laura C. Seeff, Marjolein van Ballegooijen, S. Luuk Goede, Lynn A. G. Ries. (2010) Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:3, 544-573
CrossRef207
Yen-Chung Chen, Cheng-Hwai Tzeng, Po-Min Chen, Jen-Kou Lin, Tzu-Chen Lin, Wei-Shone Chen, Jeng-Kae Jiang, Huann-Sheng Wang, Wei-Shu Wang. (2010) Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Science 101:2, 530-535
CrossRef208
Kyung Kee Baek, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Woo Yong Lee, Ho-Kyung Chun. (2010) Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: A Prospective Analysis in Patients with Colorectal Cancer. Cancer Research and Treatment 42:4, 185
CrossRef209
P. Thermann, T. Seufferlein. (2010) Aktuelle Therapie des Kolonkarzinoms. Der Gastroenterologe 5:1, 57-71
CrossRef210
Masaki WAKASUGI, Keisuke MINAMIMURA, Akihisa UMEMURA, Masahiro KIKUICHI, Toru HIRATA, Masayoshi SAKAMOTO, Akiko FUJII, Masaya MORI. (2010) A CASE OF RECTUS ABDOMINIS MUSCLE METASTASIS ORIGINATING FROM A RECTAL CANCER. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 71:3, 790-795
CrossRef211
Marc Van den Eynde, Ahmad Awada, Alain Hendlisz. (2010) Is Tailored Adjuvant Treatment for Colon Cancer Possible?. Clinical Colorectal Cancer 9:1, 15-21
CrossRef212
Sul Park, Jae Jin Jung, Goeng Bae Kim, Hyung Sik Yoon, Sang Hun Ko, Jae Ee Ko, Yeun Seun Lee. (2010) Interstitial Lung Disease Associated with Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leucovorin. The Korean Journal of Gastroenterology 55:5, 340
CrossRef213
Thilo Sprenger, Hilka Rothe, Kia Homayounfar, Tim Beissbarth, B. Michael Ghadimi, Heinz Becker, Torsten Liersch. (2010) Preoperative Chemoradiotherapy Does Not Necessarily Reduce Lymph Node Retrieval in Rectal Cancer Specimens—Results from a Prospective Evaluation with Extensive Pathological Work-up. Journal of Gastrointestinal Surgery 14:1, 96-103
CrossRef214
Heather B. Neuman, Jason Park, Martin R. Weiser. (2010) Randomized Clinical Trials in Colon Cancer. Surgical Oncology Clinics of North America 19:1, 183-204
CrossRef215
Timothy J. Price, Niall C. Tebbutt, Christos S. Karapetis, Eva Segelov, Nick Pavlakis, David Cunningham, Alberto F. Sobrero, Daniel G. Haller, Jeremy D. Shapiro. (2010) Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer 9:1, 8-14
CrossRef216
John D. Hainsworth, David R. Spigel, Howard A. Burris, Dianna Shipley, Cindy Farley, Ines M. Macias-Perez, John Barton, F. Anthony Greco. (2010) Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site. CancerNA-NA
CrossRef217
Yong Sang Hong, Tae Won Kim. (2010) Chemotherapy for Colorectal Cancer. Journal of the Korean Medical Association 53:7, 582
CrossRef218
Masayuki Tanaka, Tatsuya Matsuo, Daisuke Mori, Sadami Harada, Khoji Miyazaki. (2010) A Case of Signet Ring Cell Carcinoma of the Vermiform Appendix diagnosed as Acute Appendicitis at the Onset. The Japanese Journal of Gastroenterological Surgery 43:12, 1276-1281
CrossRef219
Markowitz, Sanford D., Bertagnolli, Monica M., . (2009) Molecular Basis of Colorectal Cancer. New England Journal of Medicine 361:25, 2449-2460
Full Text220
Sun Young Kim, Hee Jun Kim, Yong Sang Hong, Kyung Hae Jung, Ji Won Park, Hyo Seong Choi, Jae Hwan Oh, Sang-Jae Park, Seong Hoon Kim, Byung-Ho Nam, Hee Jin Chang, Dae Yong Kim. (2009) Resected colorectal liver metastases: Does the survival differ according to postoperative chemotherapy regimen?. Journal of Surgical Oncology 100:8, 713-718
CrossRef221
C.C. Earle, M.R. Weiser, A. Ter Veer, J.M. Skibber, J. Wilson, A. Rajput, Y.N. Wong, A.B. Benson, S. Shibata, D. Romanus, J. Niland, D. Schrag. (2009) Effect of lymph node retrieval rates on the utilization of adjuvant chemotherapy in stage II colon cancer. Journal of Surgical Oncology 100:7, 525-528
CrossRef222
Sameer Desai, Edgar Ben-Josef, Kent A. Griffith, Diane Simeone, Joel K. Greenson, Isaac R. Francis, Janet Hampton, Lisa Colletti, Alfred E. Chang, Theodore S. Lawrence, Mark M. Zalupski. (2009) Gemcitabine-Based Combination Chemotherapy Followed by Radiation With Capecitabine as Adjuvant Therapy for Resected Pancreas Cancer. International Journal of Radiation Oncology*Biology*Physics 75:5, 1450-1455
CrossRef223
Peter R. Holt, Peter Kozuch, Seetal Mewar. (2009) Colon cancer and the elderly: From screening to treatment in management of GI disease in the elderly. Best Practice & Research Clinical Gastroenterology 23:6, 889-907
CrossRef224
Balavenkatesh Kanna, Tarun K. Narang, Tegpal Atwal, Doru Paul, Sulaiman Azeez. (2009) Ethnic disparity in mortality after diagnosis of colorectal cancer among inner city minority New Yorkers. Cancer 115:23, 5550-5555
CrossRef225
G. Schuch, D. Arnold, C. Bokemeyer. (2009) Adjuvante Therapie des Kolonkarzinoms. Der Onkologe 15:12, 1215-1222
CrossRef226
Mario E Barugel, Carlos Vargas, Gabriel Krygier Waltier. (2009) Metastatic colorectal cancer: recent advances in its clinical management. Expert Review of Anticancer Therapy 9:12, 1829-1847
CrossRef227
Bhaumik B. Patel, Adhip P. N. Majumdar. (2009) Synergistic Role of Curcumin With Current Therapeutics in Colorectal Cancer: Minireview. Nutrition and Cancer 61:6, 842-846
CrossRef228
A. Reinacher-Schick, M. Pohl, W. Schmiegel. (2009) Die medikamentöse Therapie des kolorektalen Karzinoms. Der Internist 50:11, 1239-1252
CrossRef229
Arun V. Krishnan, Cindy S.-Y. Lin, Susanna B. Park, Matthew C. Kiernan. (2009) Axonal ion channels from bench to bedside: A translational neuroscience perspective. Progress in Neurobiology 89:3, 288-313
CrossRef230
Al B. Benson. (2009) Chemotherapy: Adding oxaliplatin to the equation. Nature Reviews Clinical Oncology 6:11, 620-622
CrossRef231
Ralf Gertler, Robert Rosenberg, Tibor Schuster, Helmut Friess. (2009) Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy. European Journal of Cancer 45:17, 2992-2999
CrossRef232
F. Fiore, A. Oden-Gangloff, P. Michel. (2009) Cancer colorectal métastatique et thérapies ciblées. Côlon & Rectum 3:4, 230-238
CrossRef233
Muhammad W. Saif, Stuart M. Lichtman. (2009) Chemotherapy options and outcomes in older adult patients with colorectal cancer. Critical Reviews in Oncology/Hematology 72:2, 155-169
CrossRef234
Alex Mejia, Stephanie Schulz, Terry Hyslop, David S Weinberg, Scott A Waldman. (2009) GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. Expert Review of Molecular Diagnostics 9:8, 777-785
CrossRef235
H. Ueno, K. Hase, Y. Hashiguchi, M. Ishiguro, Y. Kajiwara, H. Shimazaki, H. Mochizuki. (2009) Growth pattern in the muscular layer reflects the biological behaviour of colorectal cancer. Colorectal Disease 11:9, 951-959
CrossRef236
I. Lansdorp-Vogelaar, M. van Ballegooijen, A. G. Zauber, J. D. F. Habbema, E. J. Kuipers. (2009) Effect of Rising Chemotherapy Costs on the Cost Savings of Colorectal Cancer Screening. JNCI Journal of the National Cancer Institute 101:20, 1412-1422
CrossRef237
Ø Fluge, K Gravdal, E Carlsen, B Vonen, K Kjellevold, S Refsum, R Lilleng, T J Eide, T B Halvorsen, K M Tveit, A P Otte, L A Akslen, O Dahl. (2009) Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. British Journal of Cancer 101:8, 1282-1289
CrossRef238
Katsuki Muneoka, Yoshio Shirai, Masataka Sasaki, Toshifumi Wakai, Jun Sakata, Katsuyoshi Hatakeyama. (2009) Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX). International Journal of Clinical Oncology 14:5, 457-459
CrossRef239
S. B. Park, C. S.-Y. Lin, A. V. Krishnan, D. Goldstein, M. L. Friedlander, M. C. Kiernan. (2009) Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 132:10, 2712-2723
CrossRef240
Yuji Toiyama, Chikao Miki, Yasuhiro Inoue, Yoshinaga Okugawa, Kouji Tanaka, Masato Kusunoki. (2009) Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. International Journal of Cancer 125:7, 1657-1662
CrossRef241
Changlin Zhao, Hongqin Sun, Yang Yang, Huimian Xu. (2009) Advances in multidisciplinary treatment of rectal cancer. Clinical Oncology and Cancer Research 6:5, 367-373
CrossRef242
Carlo Aschele, Francesca Bergamo, Sara Lonardi. (2009) Chemotherapy for operable and advanced colorectal cancer. Cancer Treatment Reviews 35:6, 509-516
CrossRef243
H Pilgrim, P Tappenden, J Chilcott, M Bending, P Trueman, A Shorthouse, J Tappenden. (2009) The costs and benefits of bowel cancer service developments using discrete event simulation. Journal of the Operational Research Society 60:10, 1305-1314
CrossRef244
Carla Kurkjian, Shivaani Kummar. (2009) Advances in the Treatment of Metastatic Colorectal Cancer. American Journal of Therapeutics 16:5, 412-420
CrossRef245
Cristina Grávalos, Ignacio García-Escobar, Pilar García-Alfonso, Javier Cassinello, Diego Malón, Alfredo Carrato. (2009) Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clinical and Translational Oncology 11:8, 526-533
CrossRef246
Mary Mulcahy. (2009) Bevacizumab with 5-fluorouracil and leucovorin following hypersensitivity to oxaliplatin. Anti-Cancer Drugs 20:Special Issue 3, S30-S32
CrossRef247
N. Attal, D. Bouhassira, M. Gautron, J.N. Vaillant, E. Mitry, C. Lepère, P. Rougier, F. Guirimand. (2009) Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study. Pain 144:3, 245-252
CrossRef248
K. Okoshi, S. Nagayama, M. Furu, Y. Mori, A. Yoshizawa, J. Toguchida, Y. Sakai. (2009) A Case Report of Pathologically Complete Response of a Huge Rectal Cancer after Systemic Chemotherapy with mFOLFOX6. Japanese Journal of Clinical Oncology 39:8, 528-533
CrossRef249
Jiun-I. Lai, Cheng-Hwai Tzeng, Po-Min Chen, Jen-Kou Lin, Tzu-Chen Lin, Wei-Shone Chen, Jeng-Kae Jiang, Huann-Sheng Wang, Wei-Shu Wang. (2009) Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Science 100:7, 1261-1266
CrossRef250
Miriam Koopman, Sabine Venderbosch, Iris D. Nagtegaal, Johan H. van Krieken, Cornelis J. Punt. (2009) A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?. European Journal of Cancer 45:11, 1935-1949
CrossRef251
N. Kemeny, M. Capanu, M. D'Angelica, W. Jarnagin, D. Haviland, R. Dematteo, Y. Fong. (2009) Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Annals of Oncology 20:7, 1236-1241
CrossRef252
Frank A Sinicrope, Daniel J Sargent. (2009) Clinical implications of microsatellite instability in sporadic colon cancers. Current Opinion in Oncology 21:4, 369-373
CrossRef253
Julien Taieb, Pierre Laurent-Puig, Steven Alberts. (2009) Incidence of KRAS status in ongoing adjuvant trials in colon cancer. Current Colorectal Cancer Reports 5:3, 171-178
CrossRef254
Alain Hendlisz, Vassilis Golfinopoulos. (2009) Adjuvant trials design in colon cancer. Current Opinion in Oncology 21:4, 367-368
CrossRef255
Max Vergo, Halla Nimeiri, Al B. Benson. (2009) Adjuvant chemotherapy after neoadjuvant chemoradiation and surgery: A quest to improve survival for stage II and III rectal cancer. Current Colorectal Cancer Reports 5:3, 151-157
CrossRef256
Veena Shankaran, Polina Khrizman, Al B. Benson. (2009) Risk assessment and adjuvant systemic therapy in resected stage II colon cancer. Current Colorectal Cancer Reports 5:3, 158-165
CrossRef257
Corrado Boni, Thierry André, Maria Chiara Banzi, Tamas Hickish, Josep Tabernero, Philip Clingan, Benoist Chibaudel, Aimery Gramont. (2009) Similarities and differences between the adjuvant oxaliplatin-based trials MOSAIC and NSABP C-07. Current Colorectal Cancer Reports 5:3, 166-170
CrossRef258
Takeru Shiroiwa, Takashi Fukuda, Kojiro Shimozuma, Yasuo Ohashi, Kiichiro Tsutani. (2009) Cost-Effectiveness Analysis of Capecitabine Compared with Bolus 5-Fluorouracil/l-Leucovorin for the Adjuvant Treatment of Colon Cancer in Japan. PharmacoEconomics 27:7, 597-608
CrossRef259
Pei-Tu Ren, Bao-Chun Lu. (2009) Intestinal malrotation associated with colon cancer in an adult: Report of a case. Surgery Today 39:7, 624-627
CrossRef260
Daniel B. Brown, Jean-Francois H. Geschwind, Michael C. Soulen, Steven F. Millward, David Sacks. (2009) Society of Interventional Radiology Position Statement on Chemoembolization of Hepatic Malignancies. Journal of Vascular and Interventional Radiology 20:7, S317-S323
CrossRef261
Po-Huang LEE, Young-Suk PARK, Jia-Fu JI, Yiu-Tung FU, Vorachai RATANATHARATHORN. (2009) Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: The MASCOT study. Asia-Pacific Journal of Clinical Oncology 5:2, 101-110
CrossRef262
Yanhong Deng, Brenda F. Kurland, Jianping Wang, Jiong Bi, Wen Li, Sujata Rao, Ping Lan, Tongyu Lin, Edward Lin. (2009) High Epidermal Growth Factor Receptor Expression in Metastatic Colorectal Cancer Lymph Nodes May Be More Prognostic of Poor Survival Than in Primary Tumor. American Journal of Clinical Oncology 32:3, 245-252
CrossRef263
Paola Milla, Mario Airoldi, Günther Weber, Anne Drescher, Ulrich Jaehde, Luigi Cattel. (2009) Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anti-Cancer Drugs 20:5, 396-402
CrossRef264
Virginia Martínez Marin, Javier Castro, Cristobal Belda, Jorge Barriuso, Elena Hernández, Jaime Feliu. (2009) Therapeutic management of colorectal cancer in elderly patients: an update. Aging Health 5:3, 345-358
CrossRef265
Winson Y. Cheung, Bridget A. Neville, Craig C. Earle. (2009) Etiology of Delays in the Initiation of Adjuvant Chemotherapy and Their Impact on Outcomes for Stage II and III Rectal Cancer. Diseases of the Colon & Rectum 52:6, 1054-1064
CrossRef266
B. Nordlinger, E. Van Cutsem, T. Gruenberger, B. Glimelius, G. Poston, P. Rougier, A. Sobrero, M. Ychou, . (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Annals of Oncology 20:6, 985-992
CrossRef267
David Horst, Simone Reu, Lydia Kriegl, Jutta Engel, Thomas Kirchner, Andreas Jung. (2009) The intratumoral distribution of nuclear β-catenin is a prognostic marker in colon cancer. Cancer 115:10, 2063-2070
CrossRef268
Karin M. Hardiman, Molly Cone, Brett C. Sheppard, Daniel O. Herzig. (2009) Disparities in the treatment of colon cancer in octogenarians. The American Journal of Surgery 197:5, 624-628
CrossRef269
Robert O. Dillman, Kenneth Aaron, F. Scott Heinemann, Stephanie E. McClure. (2009) Identification of 12 or more lymph nodes in resected colon cancer specimens as an indicator of quality performance. Cancer 115:9, 1840-1848
CrossRef270
Andreas Herbst, Maike Wallner, Konstanze Rahmig, Petra Stieber, Alexander Crispin, Rolf Lamerz, Frank T. Kolligs. (2009) Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. European Journal of Gastroenterology & Hepatology 21:5, 565-569
CrossRef271
E. Van Cutsem, J. Oliveira, . (2009) Primary colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up. Annals of Oncology 20:Supplement 4, iv49-iv50
CrossRef272
W. Hohenberger, K. Weber, K. Matzel, T. Papadopoulos, S. Merkel. (2009) Standardized surgery for colonic cancer: complete mesocolic excision and central ligation - technical notes and outcome. Colorectal Disease 11:4, 354-364
CrossRef273
Jaime Feliu, María Sereno, Javier De Castro, Cristóbal Belda, Enrique Casado, Manuel González-Barón. (2009) Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use. Cancer Treatment Reviews 35:3, 246-254
CrossRef274
Oddmund Nordgård, Satu Oltedal, Hartwig Kørner, Ole Gunnar Aasprong, Kjersti Tjensvoll, Bjørnar Gilje, Reino Heikkilä. (2009) Quantitative RT-PCR Detection of Tumor Cells in Sentinel Lymph Nodes Isolated From Colon Cancer Patients with an Ex Vivo Approach. Annals of Surgery 249:4, 602-607
CrossRef275
D. Hölzel, R. Eckel, J. Engel. (2009) Metastasierung beim kolorektalen Karzinom. Der Chirurg 80:4, 331-340
CrossRef276
Chikuma Hamada. (2009) The role of meta-analysis in cancer clinical trials. International Journal of Clinical Oncology 14:2, 90-94
CrossRef277
Cathy Eng. (2009) Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nature Reviews Clinical Oncology 6:4, 207-218
CrossRef278
S. De Dosso, C. Sessa, P. Saletti. (2009) Adjuvant therapy for colon cancer: Present and perspectives. Cancer Treatment Reviews 35:2, 160-166
CrossRef279
Frances C. Wright, Calvin H.L. Law, Scott Berry, Andrew J. Smith. (2009) Clinically important aspects of lymph node assessment in colon cancer. Journal of Surgical Oncology 99:4, 248-255
CrossRef280
Michael S Braun, Chris J Twelves. (2009) Capecitabine in colorectal cancer. Therapy 6:2, 239-248
CrossRef281
Shin-Ichiro Yoshitani, Shigeki Takashima. (2009) Efficacy of Postoperative UFT (Tegafur/Uracil) Plus PSK Therapies in Elderly Patients with Resected Colorectal Cancer. Cancer Biotherapy & Radiopharmaceuticals 24:1, 35-40
CrossRef282
Rachel S Midgley, Yoko Yanagisawa, David J Kerr. (2009) Evolution of nonsurgical therapy for colorectal cancer. Nature Clinical Practice Gastroenterology & Hepatology 6:2, 108-120
CrossRef283
Wendy Kelder, Bas Inberg, Michael Schaapveld, Arend Karrenbeld, Joris Grond, Theo Wiggers, John T. Plukker. (2009) Impact of the Number of Histologically Examined Lymph Nodes on Prognosis in Colon Cancer. Diseases of the Colon & Rectum 52:2, 260-267
CrossRef284
Sung-Hyun Kim, Hyuk-Chan Kwon, Sung Yong Oh, Dong Mee Lee, Suee Lee, Jong-Hoon Lee, Mee-Sook Roh, Dae-Cheol Kim, Ki-Jae Park, Hong-Jo Choi, Hyo-Jin Kim. (2009) Prognostic Value of ERCC1, Thymidylate Synthase, and Glutathione S-Transferase π for 5-FU/Oxaliplatin Chemotherapy in Advanced Colorectal Cancer. American Journal of Clinical Oncology 32:1, 38-43
CrossRef285
Federica Bertolini, Silvana Chiara, Carmelo Bengala, Paolo Antognoni, Cristina Dealis, Sandra Zironi, Norma Malavasi, Tindaro Scolaro, Roberta Depenni, Gordana Jovic, Claudia Sonaglio, Aldo Rossi, Gabriele Luppi, Pier Franco Conte. (2009) Neoadjuvant Treatment With Single-Agent Cetuximab Followed by 5-FU, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer. International Journal of Radiation Oncology*Biology*Physics 73:2, 466-472
CrossRef286
Neel Shah, Don S Dizon. (2009) New-generation platinum agents for solid tumors. Future Oncology 5:1, 33-42
CrossRef287
Rodrigo Jover, Pedro Zapater, Antoni Castells, Xavier Llor, Montserrat Andreu, Joaquín Cubiella, Francesc Balaguer, Laura Sempere, Rosa M. Xicola, Luis Bujanda, Josep M. Reñé, Juan Clofent, Xavier Bessa, Juan D. Morillas, David Nicolás-Pérez, Elisenda Pons, Artemio Payá, Cristina Alenda. (2009) The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. European Journal of Cancer 45:3, 365-373
CrossRef288
Kenneth L. Meredith, Sarah E. Hoffe, David Shibata. (2009) The Multidisciplinary Management of Rectal Cancer. Surgical Clinics of North America 89:1, 177-215
CrossRef289
Keishi Yamashita, Masahiko Watanabe. (2009) Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Science 100:2, 195-199
CrossRef290
M. Ychou, J.-L. Raoul, J.-Y. Douillard, S. Gourgou-Bourgade, R. Bugat, L. Mineur, F. Viret, Y. Becouarn, O. Bouche, E. Gamelin, M. Ducreux, T. Conroy, J.-F. Seitz, L. Bedenne, A. Kramar. (2009) A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Annals of Oncology 20:4, 674-680
CrossRef291
Yong Sang Hong, Tae Won Kim. (2009) Chemotherapy for Colorectal Cancer. The Korean Journal of Gastroenterology 54:6, 355
CrossRef292
Hiroyuki SAEKI, Norio YUKAWA, Insop HAN, Akio HIGUCHI, Hiroshi TAMAGAWA, Jun FUJISAWA, Hiroshi MATSUKAWA, Yasushi RINO, Munetaka MASUDA. (2009) Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) 34:5, 889-893
CrossRef293
ROBERT E. PETRAS, WENDY L. FRANKEL. 2009. Large Intestine (Colon). , 755-836.
CrossRef294
Vassiliki L. Tsikitis, David L. Larson, Bruce G. Wolff, Gregory Kennedy, Nancy Diehl, Rui Qin, Eric J. Dozois, Robert R. Cima. (2009) Survival in Stage III Colon Cancer Is Independent of the Total Number of Lymph Nodes Retrieved. Journal of the American College of Surgeons 208:1, 42-47
CrossRef295
Josepa Ribes, Matilde Navarro, Ramon Clèries, Laura Esteban, Laura Pareja, Gemma Binefa, Mercé Peris, Esteve Fernández, Josep Maria Borràs. (2009) Colorectal cancer mortality in Spain: trends and projections for 1985–2019. European Journal of Gastroenterology & Hepatology 21:1, 92-100
CrossRef296
Thomas Falta, Gunda Koellensperger, Alexander Standler, Wolfgang Buchberger, Robert M. Mader, Stephan Hann. (2009) Quantification of cisplatin, carboplatin and oxaliplatin in spiked human plasma samples by ICP-SFMS and hydrophilic interaction liquid chromatography (HILIC) combined with ICP-MS detection. Journal of Analytical Atomic Spectrometry 24:10, 1336
CrossRef297
Yutaka Ogata, Hidetsugu Murakami, Teruo Sasatomi, Nobuya Ishibashi, Shinjiro Mori, Masataka Ushijima, Yoshito Akagi, Kazuo Shirouzu. (2009) Elevated preoperative serum carcinoembrionic antigen level may be an effective indicator for needing adjuvant chemotherapy after potentially curative resection of stage II colon cancer. Journal of Surgical Oncology 99:1, 65-70
CrossRef298
Yoshiko Miyazaki, Tomohiko Harada, Tomohide Akase, Ichiro Arakawa, Tadao Inoue. (2009) Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan. Clinical Therapeutics 31, 2433-2441
CrossRef299
Michael Gensheimer, Catherine A. Jones, Cornelia R. Graves, Nipun B. Merchant, A. Craig Lockhart. (2009) Administration of oxaliplatin to a pregnant woman with rectal cancer. Cancer Chemotherapy and Pharmacology 63:2, 371-373
CrossRef300
Vicky Goh, Steve Halligan, David M. Wellsted, Clive I. Bartram. (2009) Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study. European Radiology 19:1, 79-89
CrossRef301
Hiroaki MIENO, Taira KINOSHITA, Masaru KONISHI, Toshio NAKAGOHRI, Shinichirou TAKAHASHI, Naoto GOTOHDA. (2009) A RECTAL CANCER CASE WITH RESECTION OF PANCREATIC METASTASIS OCCURRING AFTER THREE PULMONARY METASTASIS RESECTIONS. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 70:1, 163-169
CrossRef302
Bert H O'Neil, Richard M Goldberg. (2009) What is the standard chemotherapy for colorectal cancer patients with resectable liver metastases?. Nature Clinical Practice Oncology 6:1, 14-16
CrossRef303
Muhammad Wasif Saif, Angeline The, Leslie Ledbetter. (2009) Oxaliplatin-Mediated Autoimmune Thrombocytopenia. Clinical Colorectal Cancer 8:1, 61-62
CrossRef304
Frankline K. Keter, Stonard Kanyanda, Sylvester S. L. Lyantagaye, James Darkwa, D. Jasper G. Rees, Mervin Meyer. (2008) In vitro evaluation of dichloro-bis(pyrazole)palladium(II) and dichloro-bis(pyrazole)platinum(II) complexes as anticancer agents. Cancer Chemotherapy and Pharmacology 63:1, 127-138
CrossRef305
Laura Raftery, Hanna Kelly Sanoff, Richard Goldberg. (2008) Colon Cancer in Older Adults. Seminars in Oncology 35:6, 561-568
CrossRef306
Derek G. Power, Stuart M. Lichtman. (2008) Adjuvant and Palliative Chemotherapy for Colon Cancer in the Elderly Patient. Seminars in Colon and Rectal Surgery 19:4, 239-246
CrossRef307
M. Kornmann, A. Formentini, C. Ette, D. Henne-Bruns, M. Kron, S. Sander, W. Baumann, E.-D. Kreuser, L. Staib, K.H. Link. (2008) Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. European Journal of Surgical Oncology (EJSO) 34:12, 1316-1321
CrossRef308
Ryo Takagawa, Syoichi Fujii, Mitsuyoshi Ohta, Yasuhiko Nagano, Chikara Kunisaki, Shigeru Yamagishi, Shunichi Osada, Yasushi Ichikawa, Hiroshi Shimada. (2008) Preoperative Serum Carcinoembryonic Antigen Level as a Predictive Factor of Recurrence After Curative Resection of Colorectal Cancer. Annals of Surgical Oncology 15:12, 3433-3439
CrossRef309
M. Früh, S. Gillessen, T. Cerny, R. Demmer, G. D’Addario. (2008) Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. Lung Cancer 62:3, 344-350
CrossRef310
Yu-Ning Wong. (2008) Financial Consequences of Improved Treatments for Colorectal Cancer. Seminars in Colon and Rectal Surgery 19:4, 247-252
CrossRef311
David R Fogelman, Scott Kopetz, Cathy Eng. (2008) Emerging drugs for colorectal cancer. Expert Opinion on Emerging Drugs 13:4, 629-642
CrossRef312
U. Laffer, U. Metzger, P. Aeberhard, M. Lorenz, F. Harder, R. Maibach, M. Zuber, R. Herrmann. (2008) Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial. International Journal of Colorectal Disease 23:12, 1233-1241
CrossRef313
Toshiaki Watanabe. (2008) Chemoradiotherapy and adjuvant chemotherapy for rectal cancer. International Journal of Clinical Oncology 13:6, 488-497
CrossRef314
Hanna K. Sanoff, Howard L. McLeod. (2008) Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics. Seminars in Colon and Rectal Surgery 19:4, 226-230
CrossRef315
David P. Ryan. (2008) Chemotherapeutic Strategies for Resectable Colorectal Liver Metastases. Seminars in Colon and Rectal Surgery 19:4, 203-206
CrossRef316
W. Eisterer. (2008) Colorectal cancer. memo - Magazine of European Medical Oncology 1:4, 253-257
CrossRef317
Jing Jin, Ye-Xiong Li, Jin-Wan Wang, Wei-Hu Wang, Yue-Ping Liu, Kai Wang, Hui Fang, Zhi-Xiang Zhou, Ai-Ping Zhou, Zi-Hao Yu. (2008) Phase I Study of Oxaliplatin in Combination With Capecitabine and Radiotherapy as Postoperative Treatment for Stage II and III Rectal Cancer. International Journal of Radiation Oncology*Biology*Physics 72:3, 671-677
CrossRef318
Marwan G. Fakih, Kelli BullardDunn, Gary Y. Yang, Lakshmi Pendyala, Karoly Toth, Chris Andrews, Youcef M. Rustum, Mary Ellen Ross, Charles LeVea, Ajithkumar Puthillath, Young-Mee Park, Ashwani Rajput. (2008) Phase II Study of Weekly Intravenous Oxaliplatin Combined With Oral Daily Capecitabine and Radiotherapy With Biologic Correlates in Neoadjuvant Treatment of Rectal Adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics 72:3, 650-657
CrossRef319
S. Lopatriello, D. Amoroso, S. Donati, O. Alabiso, L. Forti, A. Fornasiero, A. Smergo, A. Lalli, C. Iacono, A. Lucenti, L. D’Alonzo, C. Negrini. (2008) The CAP-CR study: Direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine. European Journal of Cancer 44:17, 2615-2622
CrossRef320
Laura Sempere, Rodrigo Jover. (2008) Nuevas perspectivas en la predicción de la respuesta a la quimioterapia en el cáncer colorrectal. Gastroenterología y Hepatología 31:9, 580-586
CrossRef321
Tianhong Li, Wancai Yang, Maomi Li, Do-Sun Byun, Chang Tong, Shannon Nasser, Min Zhuang, Diego Arango, John M. Mariadason, Leonard H. Augenlicht. (2008) Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Molecular Nutrition & Food Research 52:11, 1289-1299
CrossRef322
Alexia Kagiava, Anastasia Tsingotjidou, Christos Emmanouilides, George Theophilidis. (2008) The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. NeuroToxicology 29:6, 1100-1106
CrossRef323
Sara Arévalo Lobera, Naiara Sagastibeltza Mariñelarena, Ibone Elejoste Echeberría, Mireia Melé Olivé, Larraitz Egaña Otaño, Laura Basterretxea Badiola, Adelaida Casta Muñoa, Mikel Azkue Gabilondo. (2008) Fatal pneumonitis induced by oxaliplatin. Clinical and Translational Oncology 10:11, 764-767
CrossRef324
A Hisashige, S Yoshida, S Kodaira. (2008) Cost-effectiveness of adjuvant chemotherapy with uracil–tegafur for curatively resected stage III rectal cancer. British Journal of Cancer 99:8, 1232-1238
CrossRef325
Francesco PICCOLO, Kynan T FEENEY, Anthony E TRIBE, Phil J THOMPSON, Michael J MILLWARD, Guy A van HAZEL. (2008) Oxaliplatin-induced interstitial lung disease. Asia-Pacific Journal of Clinical Oncology 4:3, 175-180
CrossRef326
Chaoying Liu, Qing Sun, Xiaosheng Hang, Baoliang Zhong, Daoyuan Wang. (2008) Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer. Anti-Cancer Drugs 19:8, 825-831
CrossRef327
Bruce Montgomery, Philip Lavori, Mark Garzotto, Kelvin Lee, Mary Brophy, Surai Thaneemit-Chen, William Kelly, Joseph Basler, Robert Ringer, Wei Yu, Alice Whittemore, Daniel W. Lin. (2008) Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy After Prostatectomy, a Phase III Randomized Study of Prostatectomy Versus Prostatectomy with Adjuvant Docetaxel for Patients with High-Risk, Localized Prostate Cancer. Urology 72:3, 474-480
CrossRef328
Ana Belén Custodio Carretero, José Ángel García Sáenz, José Luis González Larriba, Jana Bobokova, Antonio Calles Blanco, Florentino Hernando Trancho, Beatriz García Paredes, Laura Rodríguez Lajusticia, Eduardo Díaz-Rubio García. (2008) Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review. Clinical and Translational Oncology 10:9, 560-571
CrossRef329
Constantine P. Spanos, Apostolos Mamopoulos, Apostolos Tsapas, Theodore Syrakos, Dimitris Kiskinis. (2008) Female fertility and colorectal cancer. International Journal of Colorectal Disease 23:8, 735-743
CrossRef330
Jaume Capdevila, Elena Elez, Sergio Peralta, Teresa Macarulla, Francisco Javier Ramos, Josep Tabernero. (2008) Oxaliplatin-based chemotherapy in the management of colorectal cancer. Expert Review of Anticancer Therapy 8:8, 1223-1236
CrossRef331
K. K. F. TSOI, S. S. M. NG, M. C. M. LEUNG, J. J. Y. SUNG. (2008) Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Alimentary Pharmacology & Therapeutics 28:3, 353-363
CrossRef332
Francesco Recchia, Giampiero Candeloro, Stefano Necozione, Massimo Bratta, Roberta Bisegna, Silvio Rea. (2008) Alternating XELFOX and XELFIRI in Patients With Metastatic Colorectal Cancer. American Journal of Clinical Oncology 31:4, 323-328
CrossRef333
O Capitain, M Boisdron-Celle, A-L Poirier, S Abadie-Lacourtoisie, A Morel, E Gamelin. (2008) The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. The Pharmacogenomics Journal 8:4, 256-267
CrossRef334
Bruno Vincenzi, Gaia Schiavon, Francesco Pantano, Daniele Santini, Giuseppe Tonini. (2008) Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Nature Clinical Practice Oncology 5:8, 455-465
CrossRef335
Jim Cassidy. (2008) Radio-chemotherapy in rectal cancer. European Journal of Cancer 44:12, 1620-1621
CrossRef336
Toshimi Sakai, Yuichi Yamashita, Takafumi Maekawa, Kouji Mikami, Seiichiro Hoshino, Takayuki Shirakusa. (2008) Immunochemotherapy with PSK and Fluoropyrimidines Improves Long-Term Prognosis for Curatively Resected Colorectal Cancer. Cancer Biotherapy & Radiopharmaceuticals 23:4, 461-468
CrossRef337
André B. P. van Kuilenburg, Heinz-Josef Klumpen, Anneke M. Westermann, Lida Zoetekouw, Piet J. M. Bakker, Henk-Jan Guchelaar, Dick J. Richel. (2008) Altered Dihydropyrimidine Dehydrogenase Activity Associated with Mild Toxicity in Patients Treated with 5-Fluorouracil Containing Chemotherapy. Nucleosides, Nucleotides and Nucleic Acids 27:6-7, 726-732
CrossRef338
D. Papamichael, R. Audisio, J.-C. Horiot, B. Glimelius, J. Sastre, E. Mitry, E. Van Cutsem, M. Gosney, C.-H. Kohne, M. Aapro. (2008) Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Annals of Oncology 20:1, 5-16
CrossRef339
A-E Carsin, L Sharp, D P Cronin-Fenton, A Ó Céilleachair, H Comber. (2008) Inequity in colorectal cancer treatment and outcomes: a population-based study. British Journal of Cancer 99:2, 266-274
CrossRef340
V Gouyer, D Fontaine, P Dumont, O de Wever, H Fontayne-Devaud, E Leteurtre, S Truant, D Delacour, H Drobecq, J-P Kerckaert, Y de Launoit, M Bracke, C Gespach, J-L Desseyn, G Huet. (2008) Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells. Oncogene 27:29, 4024-4033
CrossRef341
Sujatha Nallapareddy, S. Gail Eckhardt, Wells Messersmith. (2008) Irinotecan versus oxaliplatin for adjuvant colon cancer therapy: Why do the results differ?. Current Colorectal Cancer Reports 4:3, 167-172
CrossRef342
P. Deepa, P. Kolandaivel, K. Senthilkumar. (2008) Interactions of anticancer drugs with usual and mismatch base pairs — Density functional theory studies. Biophysical Chemistry 136:1, 50-58
CrossRef343
Fumitake Hata, Kazuaki Sasaki, Koichi Hirata, Susumu Yamamitsu, Tetsuhiko Shirasaka. (2008) Efficacy of a continuous venous infusion of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: A prospective randomized trial. Surgery Today 38:7, 623-632
CrossRef344
Michael A. Choti, Timothy M. Pawlik. (2008) Neoadjuvant or adjuvant therapy for patients with resectable liver metastases. Current Colorectal Cancer Reports 4:3, 160-166
CrossRef345
E. Barrow, R. McMahon, D. G. Evans, E. Levine, J. Hill. (2008) Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer. British Journal of Surgery 95:7, 868-875
CrossRef346
A C Pieck, A Drescher, K G Wiesmann, J Messerschmidt, G Weber, D Strumberg, R A Hilger, M E Scheulen, U Jaehde. (2008) Oxaliplatin-DNA adduct formation in white blood cells of cancer patients. British Journal of Cancer 98:12, 1959-1965
CrossRef347
G. Lurje, W. Zhang, A. M. Schultheis, D. Yang, S. Groshen, A. E. Hendifar, H. Husain, M. A. Gordon, F. Nagashima, H. M. Chang, H.-J. Lenz. (2008) Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Annals of Oncology 19:10, 1734-1741
CrossRef348
H. Zwierzina. (2008) Adjuvant therapy of stage II colorectal cancer – who will benefit from treatment?. memo - Magazine of European Medical Oncology 1:2, 75-77
CrossRef349
G. Kornek, W. Scheithauer, R. Anghel, G. Bodoky, F. Ciardiello, T. Ciuleanu, R. Glynne-Jones, T. Gruenberger, I. Koza, J. Ocvirk, L. Petruzelka, G. Poston, G. Ramadori, W. Schmiegel, S. Segaert, J. Tabernero, H. Zwierzina, C. Zielinski. (2008) Consensus on the medical treatment of colon cancer. memo - Magazine of European Medical Oncology 1:2, 79-90
CrossRef350
Sara Lonardi, Carlo Aschele, Lara Maria Pasetto, Salvatore Pucciarelli, Maria Luisa Friso, Antonio Jirillo, Silvio Monfardini. (2008) Multidisciplinary management is strongly suggested in elderly patients with rectal carcinoma. Aging Health 4:3, 287-298
CrossRef351
Lara Maria Pasetto, Antonio Jirillo, Sara Lonardi, Cristina Falci, Silvio Monfardini. (2008) Colon cancer in elderly patients: what is the best treatment?. Aging Health 4:3, 279-286
CrossRef352
Lan Huang, Kathleen A Cronin, Karen A. Johnson, Angela B. Mariotto, Eric J. Feuer. (2008) Improved survival time: What can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?. Cancer 112:10, 2289-2300
CrossRef353
Dena J. Fischer, Gary D. Klasser, Joel B. Epstein. (2008) Cancer and Orofacial Pain. Oral and Maxillofacial Surgery Clinics of North America 20:2, 287-301
CrossRef354
Brian M. Wolpin, Robert J. Mayer. (2008) Systemic Treatment of Colorectal Cancer. Gastroenterology 134:5, 1296-1310.e1
CrossRef355
Michael Castro. (2008) Peripheral sensory neuropathy—fighting cold with cold. The Lancet Oncology 9:5, 415-416
CrossRef356
W. Kelder, B. Inberg, J.T.M. Plukker, H. Groen, P.C. Baas, A.T.M.G. Tiebosch. (2008) Effect of modified Davidson's fixative on examined number of lymph nodes and TNM-stage in colon carcinoma. European Journal of Surgical Oncology (EJSO) 34:5, 525-530
CrossRef357
M.T. Seymour, I. Trigonis, P.J. Finan, F. Halstead, R. Dunham, G. Wilson, D. Farrugia, J.D. Chester, J. King, C.B. Brown, M.L. Slevin, S.P. Joel. (2008) A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer. European Journal of Surgical Oncology (EJSO) 34:4, 403-409
CrossRef358
Tzeela Cohen, Diana Prus, Jinru Shia, Bassam Abu-Wasel, Meir G. Pinto, Herbert R. Freund, Alexander Stojadinovic, Anna Grakov, Tamar Peretz, Aviram Nissan. (2008) Expression of P53, P27 and KI-67 in colorectal cancer patients of various ethnic origins: Clinical and tissue microarray based analysis. Journal of Surgical Oncology 97:5, 416-422
CrossRef359
Hamed Kargozaran, Morton Kahlenberg, Vijay P. Khatri. (2008) The Implications of Colorectal Cancer Molecular Biology in Clinical Practice. Surgical Oncology Clinics of North America 17:2, 341-355
CrossRef360
Hilary Glen, Jim Cassidy. (2008) Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial. Expert Review of Anticancer Therapy 8:4, 547-551
CrossRef361
Yeon Hee Park, Jae-Lyun Lee, Baek-Yeol Ryoo, Min-Hee Ryu, Sung Hyun Yang, Bong Seog Kim, Dong Bok Shin, Heung Moon Chang, Tae Won Kim, Young Jin Yuh, Yoon-Koo Kang. (2008) Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemotherapy and Pharmacology 61:4, 623-629
CrossRef362
P. Gibbs, D. Handolias, S. McLaughlin, M. Chapman, J. Johns, I. Faragher. (2008) Single-institution experience of adjuvant 5-fluorouracil-based chemotherapy for stage III colon cancer. Internal Medicine Journal 38:4, 265-269
CrossRef363
Yu Jo Chua, John R Zalcberg. (2008) Progress and challenges in the adjuvant treatment of stage II and III colon cancers. Expert Review of Anticancer Therapy 8:4, 595-604
CrossRef364
Timothy R. Asmis, Leonard Saltz. (2008) Systemic Therapy for Colon Cancer. Gastroenterology Clinics of North America 37:1, 287-295
CrossRef365
Arun V. Krishnan, Cindy S.-Y. Lin, Susanna B. Park, Matthew C. Kiernan. (2008) Assessment of nerve excitability in toxic and metabolic neuropathies. Journal of the Peripheral Nervous System 13:1, 7-26
CrossRef366
Nicolas Moosmann, Volker Heinemann. (2008) Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. Expert Review of Anticancer Therapy 8:3, 319-329
CrossRef367
Dominique Elias, Diane Goéré, Daniela Di Pietrantonio, Valérie Boige, David Malka, Niaz Kohneh-Shahri, Clarisse Dromain, Michel Ducreux. (2008) Results of Systematic Second-Look Surgery in Patients at High Risk of Developing Colorectal Peritoneal Carcinomatosis. Annals of Surgery 247:3, 445-450
CrossRef368
N. Ansorge, W. Schmidt, P. Ritter. (2008) Adjuvante Therapie des Kolon- und Rektumkarzinoms. Der Gastroenterologe 3:2, 119-125
CrossRef369
Bernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, Graeme J Poston, Peter M Schlag, Philippe Rougier, Wolf O Bechstein, John N Primrose, Euan T Walpole, Meg Finch-Jones, Daniel Jaeck, Darius Mirza, Rowan W Parks, Laurence Collette, Michel Praet, Ullrich Bethe, Eric Van Cutsem, Werner Scheithauer, Thomas Gruenberger. (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. The Lancet 371:9617, 1007-1016
CrossRef370
Alfredo Carrato, Javier Gallego-Plazas, Carmen Guillén-Ponce. (2008) Capecitabine plus oxaliplatin for the treatment of colorectal cancer. Expert Review of Anticancer Therapy 8:2, 161-174
CrossRef371
Scott A Waldman, Andre Terzic. (2008) Therapeutic burden in cancer revealed by molecular staging. Biomarkers in Medicine 2:1, 1-3
CrossRef372
Georg Lurje, Wu Zhang, Dongyun Yang, Susan Groshen, Andrew E. Hendifar, Hatim Husain, Fumio Nagashima, Heung M. Chang, William Fazzone, Robert D. Ladner, Alexandra Pohl, Yan Ning, Syma Iqbal, Anthony El-Khoueiry, Heinz-Josef Lenz. (2008) Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenetics and Genomics 18:2, 161-168
CrossRef373
Julien Taieb, Pierre Laurent Puig, Laurent Bedenne. (2008) Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial. Expert Review of Anticancer Therapy 8:2, 183-189
CrossRef374
T. Kowalski, C. Maier, A. Reinacher-Schick, U. Schlegel. (2008) Schmerzhaftes Hyperexzitabilitätssyndrom unter Oxaliplatin-haltiger Chemotherapie. Der Schmerz 22:1, 16-23
CrossRef375
E. Mitry. (2008) 5FU et lévamisole comme traitement adjuvant des cancers coliques réséqués. Côlon & Rectum 2:1, 37-39
CrossRef376
Fabio Puglisi, Giuseppe Aprile, Gianpiero Fasola. (2008) Hot topics and landmark studies from the 43rd annual meeting of the American Society of Clinical Oncology. Anti-Cancer Drugs 19:2, 221-233
CrossRef377
U. Graeven, M. M. Heiss. (2008) Kolonkarzinom. best practice onkologie 3:1, 4-12
CrossRef378
Chris Twelves. (2008) Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?. Nature Clinical Practice Oncology 5:2, 72-73
CrossRef379
Jennica K.S. Ng, Stefan J. Urbanski, Naurang Mangat, Andrew McKay, Francis R. Sutherland, Elijah Dixon, Scot Dowden, Scott Ernst, Oliver F. Bathe. (2008) Colorectal liver metastases contract centripetally with a response to chemotherapy. Cancer 112:2, 362-371
CrossRef380
Bhaumik B. Patel, Radha Sengupta, Sadia Qazi, Hetal Vachhani, Yingjie Yu, Arun K. Rishi, Adhip P.N. Majumdar. (2008) Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. International Journal of Cancer 122:2, 267-273
CrossRef381
Raya Saab, Wayne L Furman. (2008) Epidemiology and Management Options for Colorectal Cancer in Children. Pediatric Drugs 10:3, 177-192
CrossRef382
Kellie L. Mathis, Heidi Nelson, John H. Pemberton, Michael G. Haddock, Leonard L. Gunderson. (2008) Unresectable Colorectal Cancer Can Be Cured With Multimodality Therapy. Transactions of the ... Meeting of the American Surgical Association 126, 235-241
CrossRef383
Kyoko Seki, Kenzou Senzaki, Yasuo Tsuduki, Takeshi Ioroi, Michiko Fujii, Hiroko Yamauchi, Yukinari Shiraishi, Izumi Nakata, Kohshi Nishiguchi, Teruhisa Matsubayashi, Yoshihide Takakubo, Noboru Okamura, Toshiyuki Sakaeda. (2008) Multicenter Trial on Hypersensitivity Reactions following Treatment with FOLFOX Regimens. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 34:10, 919-926
CrossRef384
Antonio Jirillo, Michaela Stefani, Federica Vascon, Sara Lonardi. (2008) Adjuvant Systemic Chemotherapy with 5-Fluorouracil and Leucovorin in Colon Cancer: A Monoinstitutional Institutional Experience. Immunopharmacology and Immunotoxicology 30:2, 235-242
CrossRef385
Hidefumi KUBO, Masahiro KITAHARA, Sinsuke KANEKIYO, Kosuke TADA, Makoto MIYAHARA, Hiroyasu HASEGAWA. (2008) A Case of Rectal Cancer with Simultaneous Liver Metastasis and Heterochronous Ovarian Metastasis. Yamaguchi Medical Journal 57:6, 209-215
CrossRef386
Sherry J. Lim, Barry W. Feig, Huamin Wang, Kelly K. Hunt, Miguel A. Rodriguez-Bigas, John M. Skibber, Vickie Ellis, Karen Cleary, George J. Chang. (2008) Sentinel Lymph Node Evaluation Does Not Improve Staging Accuracy in Colon Cancer. Annals of Surgical Oncology 15:1, 46-51
CrossRef387
Francesco Di Costanzo, Roberto Ravasio, Alberto Sobrero, Oscar Bertetto, Orazio Vinante, Gabriele Luppi, Roberto Labianca, Dino Amadori, Carlo Barone, Marco Carlo Merlano, Flavia Longo, Giovanni Mansueto, Lorenzo Antonuzzo, Silvia Gasperoni. (2008) Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukesʼ C Colon Cancer. Clinical Drug Investigation 28:10, 645-655
CrossRef388
Pasquale Comella, Rossana Casaretti, Claudia Sandomenico, Antonio Avallone, Luca Franco. (2008) Capecitabine, Alone and in Combination, in the Management of Patients with Colorectal Cancer. Drugs 68:7, 949-961
CrossRef389
Matthew G. Mutch. (2007) Molecular profiling and risk stratification of adenocarcinoma of the colon. Journal of Surgical Oncology 96:8, 693-703
CrossRef390
QUASAR Collaborative Group. (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. The Lancet 370:9604, 2020-2029
CrossRef391
G. Wichert, T. Seufferlein. (2007) Adjuvante Chemotherapie bei soliden Tumoren des Gastrointestinaltrakts. Der Internist 48:12, 1335-1342
CrossRef392
Andreas Binder, Maike Stengel, Rainer Maag, Gunnar Wasner, Robert Schoch, Frank Moosig, Bernhard Schommer, Ralf Baron. (2007) Pain in oxaliplatin-induced neuropathy – Sensitisation in the peripheral and central nociceptive system. European Journal of Cancer 43:18, 2658-2663
CrossRef393
David Cunningham, Naureen Starling. (2007) Adjuvant chemotherapy of colorectal cancer. The Lancet 370:9604, 1980-1981
CrossRef394
Yih-Huei Uen, Shiu-Ru Lin, Deng-Chyang Wu, Yu-Chung Su, Jeng-Yih Wu, Tian-Lu Cheng, Chin-Wen Chi, Jaw-Yuan Wang. (2007) Prognostic Significance of Multiple Molecular Markers for Patients With Stage II Colorectal Cancer Undergoing Curative Resection. Annals of Surgery 246:6, 1040-1046
CrossRef395
Rob Glynne-Jones, Pawan Mathur, Colin Elton, Matthew L. Train. (2007) Multimodal treatment of rectal cancer. Best Practice & Research Clinical Gastroenterology 21:6, 1049-1070
CrossRef396
M. Gelos, J. Gelhaus, P. Mehnert, G. Bonhag, M. Sand, S. Philippou, B. Mann. (2007) Factors influencing lymph node harvest in colorectal surgery. International Journal of Colorectal Disease 23:1, 53-59
CrossRef397
J. Philip Kuebler, Linda Colangelo, Michael J. O'Connell, Roy E. Smith, Greg Yothers, Mirsada Begovic, Bridget Robinson, Thomas E. Seay, Norman Wolmark. (2007) Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin. Cancer 110:9, 1945-1950
CrossRef398
Eléonore Alter, Jean-Marc Phelip, Jean-Noel Guilhot, Michel Matysiak, Michel Vermorel, Xavier Roblin. (2007) Adjuvant chemotherapy for stage II colon cancer: influence of care structuresʼ characteristics on a controversial clinical practice. European Journal of Gastroenterology & Hepatology 19:11, 995-1001
CrossRef399
Fumihiro Tanaka. (2007) UFT (Tegafur and Uracil) as Postoperative Adjuvant Chemotherapy for Solid Tumors (Carcinoma of the Lung, Stomach, Colon/Rectum, and Breast): Clinical Evidence, Mechanism of Action, and Future Direction. Surgery Today 37:11, 923-943
CrossRef400
W Schippinger, H Samonigg, R Schaberl-Moser, R Greil, R Thödtmann, J Tschmelitsch, M Jagoditsch, G G Steger, R Jakesz, F Herbst, F Hofbauer, H Rabl, P Wohlmuth, M Gnant, J Thaler. (2007) A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. British Journal of Cancer 97:8, 1021-1027
CrossRef401
P Österlund, T Ruotsalainen, R Korpela, M Saxelin, A Ollus, P Valta, M Kouri, I Elomaa, H Joensuu. (2007) Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. British Journal of Cancer 97:8, 1028-1034
CrossRef402
Harpreet S. Wasan. 2007. Multidisciplinary Team Management of Colorectal Cancer. .
CrossRef403
Roberto Petrioli, Alessandra Pascucci, Edoardo Francini, Stefania Marsili, Angela Sciandivasci, Rossana Tassi, Serenella Civitelli, Gabriello Tanzini, Marco Lorenzi, Guido Francini. (2007) Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemotherapy and Pharmacology 61:1, 105-111
CrossRef404
Bert H. O’Neil, Joel E. Tepper. (2007) Current Options for the Management of Rectal Cancer. Current Treatment Options in Oncology 8:5, 331-338
CrossRef405
Jian Ping Xiong, Ling Zhang, Lu Xing Zhong, Feng Qiu, Jun Xu, Qing Song Tao, Xiao Jun Xiang, Feng Yu, Xiao Mei Tang. (2007) A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. Anti-Cancer Drugs 18:9, 1103-1107
CrossRef406
Olivia Aranha, Al B. Benson. (2007) Adjuvant therapy for Colon Cancer. Current Gastroenterology Reports 9:5, 415-421
CrossRef407
Claudia Hriesik, Ramesh K. Ramanathan, Steven J. Hughes. (2007) Update for Surgeons: Recent and Noteworthy Changes in Therapeutic Regimens for Cancer of the Colon and Rectum. Journal of the American College of Surgeons 205:3, 468-478.e1
CrossRef408
A. Hoffmann, B. Rau, S. Koswig. (2007) Kolorektales Karzinom. Der Onkologe 13:9, 813-822
CrossRef409
Catherine Hubert, Christine Sempoux, Yves Horsmans, Jacques Rahier, Yves Humblet, Jean-Pascal Machiels, Antonino Ceratti, Jean-Luc Canon, Jean-François Gigot. (2007) Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?. Liver International 27:7, 938-943
CrossRef410
Ping Liu, Jianhui Liu, Daoqi Zhu, Jin’an Ma, Chunhong Hu. (2007) Clinical observation of colon carcinoma treated with Boerning capsules plus FOLFOX4 regimen. The Chinese-German Journal of Clinical Oncology 6:4, 328-330
CrossRef411
Florent Toscano, Béatrice Parmentier, Zineb El Fajoui, Yann Estornes, Jean-Alain Chayvialle, Jean-Christophe Saurin, Jacques Abello. (2007) p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells. Biochemical Pharmacology 74:3, 392-406
CrossRef412
Nimit Singhal, Deepti Singhal, Nimit Singhal. 2007. Adjuvant chemotherapy for small intestine adenocarcinoma. .
CrossRef413
C. J. A. Punt, M. Buyse, C.-H. Kohne, P. Hohenberger, R. Labianca, H. J. Schmoll, L. Pahlman, A. Sobrero, J.-Y. Douillard. (2007) Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials. JNCI Journal of the National Cancer Institute 99:13, 998-1003
CrossRef414
Erick Gamelin, Michele Boisdron-Celle, Alain Morel, Olivier Capitain, Olivier Coqueret. (2007) Adjuvant therapy for colon cancer based on pharmacogenomics?. Current Colorectal Cancer Reports 3:3, 143-149
CrossRef415
Carlos Becerra, Yull Arriaga, Edward Chu. (2007) Highlights from: Annual Meeting of the American Society of Clinical Oncology Chicago, Illinois; June 1–5, 2007. Clinical Colorectal Cancer 6:8, 556-560
CrossRef416
Vicky M. Coyle, Wendy L. Allen, Patrick G. Johnston. (2007) Could we decide adjuvant therapy of colon cancer based on microarrays?. Current Colorectal Cancer Reports 3:3, 137-142
CrossRef417
Alain Hendlisz. (2007) Don??t believe ??? check!!. Current Opinion in Oncology 19:4, 383
CrossRef418
Stephen H. Wrzesinski, Meghan L. McGurk, Constance T. Donovan, Thomas M. Ferencz, Muhammad Wasif Saif. (2007) Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate. Anti-Cancer Drugs 18:6, 721-724
CrossRef419
Anjali Bhagra, Ravi D. Rao. (2007) Chemotherapy-induced neuropathy. Current Oncology Reports 9:4, 290-299
CrossRef420
S. Aballéa, A. Boler, A. Craig, H. Wasan. (2007) An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). European Journal of Cancer 43:11, 1687-1693
CrossRef421
Jin-Tung Liang, Kuo-Chin Huang, Hong-Shiee Lai, Po-Huang Lee, Chia-Tung Sun. (2007) Oncologic Results of Laparoscopic D3 Lymphadenectomy for Male Sigmoid and Upper Rectal Cancer with Clinically Positive Lymph Nodes. Annals of Surgical Oncology 14:7, 1980-1990
CrossRef422
Cary P. Gross, Gail J. McAvay, Zhenchao Guo, Mary E. Tinetti. (2007) The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 109:12, 2410-2419
CrossRef423
M. Julieta Corral, Ana Clopès, Matilde Navarro, Josep Ramon Germà, Josep Maria Borràs. (2007) Impacto presupuestario de los nuevos fármacos para el tratamiento del cáncer colorrectal. Medicina Clínica 129:4, 134-136
CrossRef424
Susan Jones-Bolin, Bruce Ruggeri. 2007. Orthotopic Models of Human Gastric Carcinoma in Nude Mice: Applications for Study of Tumor Growth and Progression. .
CrossRef425
R. Glynne-Jones, H. Meadows, W. Wood. (2007) Chemotherapy or No Chemotherapy in Clear Margins after Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: CHRONICLE. A Randomised Phase III Trial of Control vs. Capecitabine plus Oxaliplatin. Clinical Oncology 19:5, 327-329
CrossRef426
Suzanne KOSMIDER, Peter GIBBS. (2007) An incorrect diagnosis of metastatic colorectal cancer: The need for tissue diagnosis prior to treatment. Asia-Pacific Journal of Clinical Oncology 3:2, 106-107
CrossRef427
Brian G. Czito, Johanna C. Bendell, Christopher G. Willett, Michael A. Morse, Gerard C. Blobe, Douglas S. Tyler, John Thomas, Kirk A. Ludwig, Christopher R. Mantyh, Jill Ashton, Daohai Yu, Herbert I. Hurwitz. (2007) Bevacizumab, Oxaliplatin, and Capecitabine With Radiation Therapy in Rectal Cancer: Phase I Trial Results. International Journal of Radiation Oncology*Biology*Physics 68:2, 472-478
CrossRef428
Cristina Valls Bautista, Carme Piñol Felis, Josep M. Reñé Espinet, Juan Buenestado García, Joan Viñas Salas. (2007) Telomerase Activity is a Prognostic Factor for Recurrence and Survival in Rectal Cancer. Diseases of the Colon & Rectum 50:5, 611-620
CrossRef429
Adam S. Kibel, Eli Rosenbaum, Michael W. Kattan, Joel Picus, Robert Dreicer, Eric A. Klein, Gurkamal S. Chatta, Joel B. Nelson, Robert S. DiPaola, Bruce J. Roth, Michael S. Cookson, George Wilding, David F. Jarrard, Tomasz M. Beer, Christopher W. Ryan, Daniel P. Petrylak, Mitchell C. Benson, Alan W. Partin, Elizabeth Garrett-Mayer, Mario A. Eisenberger. (2007) Adjuvant Weekly Docetaxel for Patients With High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot Study. The Journal of Urology 177:5, 1777-1781
CrossRef430
Ki Young Chung, Leonard B. Saltz. (2007) Adjuvant Therapy of Colon Cancer: Current Status and Future Directions. The Cancer Journal 13:3, 192-197
CrossRef431
Francesco Recchia, Gaetano Saggio, Alisia Cesta, Giampiero Candeloro, Anna Blasio, Giovanna Amiconi, Marco Lombardo, Antonio Nuzzo, Angelo Lalli, Edoardo Alesse, Stefano Necozione, Silvio Rea. (2007) Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer. Cancer Immunology, Immunotherapy 56:5, 699-708
CrossRef432
Mathew Joseph, Al B. Benson. (2007) Current Issues in Rectal Cancer Chemotherapy. The Cancer Journal 13:3, 198-203
CrossRef433
J Sakamoto, C Hamada, S Yoshida, S Kodaira, M Yasutomi, T Kato, K Oba, H Nakazato, S Saji, Y Ohashi. (2007) An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer. British Journal of Cancer 96:8, 1170-1177
CrossRef434
George P Kim, Charles Erlichman. (2007) Oxaliplatin in the treatment of colorectal cancer. Expert Opinion on Drug Metabolism & Toxicology 3:2, 281-294
CrossRef435
Ami Sabharwal, David Kerr. (2007) Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Review of Anticancer Therapy 7:4, 477-487
CrossRef436
Francesco Caprioni, Giuseppe Fornarini. (2007) Bevacizumab in the treatment of metastatic colorectal cancer. Future Oncology 3:2, 141-148
CrossRef437
Udai S. Kammula, Eleanor J. Kuntz, Todd D. Francone, Zhaoshi Zeng, Jinru Shia, Ron G. Landmann, Philip B. Paty, Martin R. Weiser. (2007) Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Letters 248:2, 219-228
CrossRef438
Aimery de Gramont, Christophe Tournigand, Thierry André, Annette K. Larsen, Christophe Louvet. (2007) Adjuvant Therapy for Stage II and III Colorectal Cancer. Seminars in Oncology 34, S37-S40
CrossRef439
C Y Ngan, H Yamamoto, I Seshimo, T Tsujino, M Man-i, J-I Ikeda, K Konishi, I Takemasa, M Ikeda, M Sekimoto, N Matsuura, M Monden. (2007) Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. British Journal of Cancer 96:6, 986-992
CrossRef440
F Willeke, K Horisberger, U Kraus-Tiefenbacher, F Wenz, A Leitner, A Hochhaus, R Grobholz, A Willer, G Kähler, S Post, R-D Hofheinz. (2007) A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. British Journal of Cancer 96:6, 912-917
CrossRef441
Samuel Aballéa, Jeremy V.M. Chancellor, Maria Raikou, Michael F. Drummond, Milton C. Weinstein, Sophia Jourdan, John Bridgewater. (2007) Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 109:6, 1082-1089
CrossRef442
M Morris, C Platell, L Fritschi, B Iacopetta. (2007) Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. British Journal of Cancer 96:5, 701-707
CrossRef443
Sebastiano Buti, Matteo Ricc??, Matteo Dalla Chiesa, Bruno Copercini, Gianluca Tomasello, Matteo Brighenti, Rodolfo Passalacqua. (2007) Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report. Anti-Cancer Drugs 18:3, 297-300
CrossRef444
Allen W. Burton, Gilbert J. Fanciullo, Ralph D. Beasley, Michael J. Fisch. (2007) Chronic Pain in the Cancer Survivor: A New Frontier. Pain Medicine 8:2, 189-198
CrossRef445
Robbert J. Haas, Dennis A. Wicherts, Monique G. G. Hobbelink, Inne H. M. Borel Rinkes, Marguerite E. I. Schipper, Joke-Afke Zee, Richard Hillegersberg. (2007) Sentinel Lymph Node Mapping in Colon Cancer: Current Status. Annals of Surgical Oncology 14:3, 1070-1080
CrossRef446
Marwan Ghosn, Fadi Farhat, Joseph Kattan, Fariha Younes, Walid Moukadem, Fadi Nasr, Georges Chahine. (2007) FOLFOX-6 Combination as the First-Line Treatment of Locally Advanced and/or Metastatic Pancreatic Cancer. American Journal of Clinical Oncology 30:1, 15-20
CrossRef447
Anton J. Bilchik. (2007) Current and emerging trends in the treatment of early-stage colorectal cancer: importance of a multidisciplinary approach. Hematology/Oncology Clinics of North America 21, 8-18
CrossRef448
Stephen Shibata, Warren Chow, Paul Frankel, Agnes Juhasz, Lucille Leong, Dean Lim, Kim Margolin, Robert Morgan, Edward Newman, George Somlo, Yun Yen, Timothy Synold, David Gandara, Heinz-Josef Lenz, James Doroshow. (2007) A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. Cancer Chemotherapy and Pharmacology 59:4, 549-557
CrossRef449
Ming-Yang Lee, Muh-Hwa Yang, Jin-Hwang Liu, Chueh-Chuan Yen, Pang-Chan Lin, Hao-Wei Teng, Wei-Shu Wang, Tzeon-Jye Chiou, Po-Min Chen. (2007) Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Supportive Care in Cancer 15:1, 89-93
CrossRef450
E. Samantas, C. Dervenis, S.K. Rigatos. (2007) Adjuvant Chemotherapy for Colon Cancer: Evidence on Improvement in Survival. Digestive Diseases 25:1, 67-75
CrossRef451
F Prall. (2007) Tumour budding in colorectal carcinoma. Histopathology 50:1, 151-162
CrossRef452
Jens Martin Werner, Kurt Eger, Hans Jürgen Steinfelder. (2007) Comparison of the rapid pro-apoptotic effect of trans-ß-nitrostyrenes with delayed apoptosis induced by the standard agent 5-fluorouracil in colon cancer cells. Apoptosis 12:1, 235-246
CrossRef453
P Quirke, E Morris. (2007) Reporting colorectal cancer. Histopathology 50:1, 103-112
CrossRef454
Tomoaki Yoshimura, Michio Kimura, Mina Iwai, Eiseki Usami, Toshiya Nakao, Tadashi Yasuda. (2007) Evaluation of Safety of FOLFOX4 Regimen in Patients with Advanced and Recurrent Colorectal Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 33:6, 520-525
CrossRef455
Ajay Sahajpal, Charles M. Vollmer, Elijah Dixon, Elisa K. Chan, Alice Wei, Mark S. Cattral, Bryce R. Taylor, David R. Grant, Paul D. Greig, Steven Gallinger. (2007) Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. Journal of Surgical Oncology 95:1, 22-27
CrossRef456
Michael Geißler. (2007) Adjuvante Kolonkarzinomtherapie im Stadium II und III – Standards und Perspektiven in der Mono- oder Kombinationstherapie. Onkologie 30:2, 2-4
CrossRef457
Frank G A Jansman, Maarten J Postma, Jacobus R B J Brouwers. (2007) Cost Considerations in the Treatment of Colorectal Cancer. PharmacoEconomics 25:7, 537-562
CrossRef458
Naureen Starling, David Cunningham. (2007) Does shorter duration of chemotherapy worsen survival for elderly patients with colon cancer?. Nature Clinical Practice Oncology 4:1, 12-13
CrossRef459
2007. C. , 39-51.
CrossRef460
Sharlene Gill, A. William Blackstock, Richard M. Goldberg. (2007) Colorectal Cancer. Mayo Clinic Proceedings 82:1, 114-129
CrossRef461
S. Gill, A. W. Blackstock, R. M. Goldberg. (2007) Colorectal Cancer. Mayo Clinic Proceedings 82:1, 114-129
CrossRef462
J Feliu, J Castro, C Belda, A Sundlov, E Casado, M González-Barón. (2006) Treatment options for colorectal cancer in the elderly. Aging Health 2:6, 931-942
CrossRef463
Anna Maria Valentini, Raffaele Armentano, Michele Pirrelli, Maria L. Caruso. (2006) Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: The state of the art. Cancer Treatment Reviews 32:8, 607-618
CrossRef464
Kelly W MOK, David GOLDSTEIN. (2006) Hypersensitivity reactions to oxaliplatin: Can patients be rechallenged?. Asia-Pacific Journal of Clinical Oncology 2:4, 175-179
CrossRef465
Stephen P. Ackland, Stephen J. Clarke, Phillip Beale, Godefridus J. Peters. (2006) Thymidylate synthase inhibitors. Update on Cancer Therapeutics 1:4, 403-427
CrossRef466
Hideaki Yano, Yukio Saito, Yujiro Kirihara, Junya Takashima. (2006) Tumor Invasion of Lymph Node Capsules in Patients with Dukes C Colorectal Adenocarcinoma. Diseases of the Colon & Rectum 49:12, 1867-1877
CrossRef467
S Eggington, P Tappenden, A Pandor, S Paisley, M Saunders, M Seymour, P Sutcliffe, J Chilcott. (2006) Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. British Journal of Cancer 95:9, 1195-1201
CrossRef468
V.S. Ramani, S.W. Gollins, H. Wong. (2006) Weekly Fluorouracil at 425mg/m2 plus Low-dose Folinic Acid for 24 Weeks as Adjuvant Treatment for Colorectal Cancer: Assessment of Toxicity and Delivery. Clinical Oncology 18:9, 649-657
CrossRef469
Dominique Arsene, Marie-Pierre Galais, Karine Bouhier-Leporrier, Jean-Marie Reimund. (2006) Recent developments in colorectal cancer treatment by monoclonal antibodies. Expert Opinion on Biological Therapy 6:11, 1175-1192
CrossRef470
Benjamin Djulbegovic, Heloisa P. Soares, Ambuj Kumar. (2006) What kind of evidence do patients and practitioners need: Evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. Cancer Treatment Reviews 32:7, 572-576
CrossRef471
Iris Vogelaar, Marjolein van Ballegooijen, Deborah Schrag, Rob Boer, Sidney J. Winawer, J. Dik F. Habbema, Ann G. Zauber. (2006) How much can current interventions reduce colorectal cancer mortality in the U.S.?. Cancer 107:7, 1624-1633
CrossRef472
Danish Mazhar, Justin Stebbing, Wolfgang Heller. (2006) Recent advances in the systemic management of colorectal cancer. Future Oncology 2:5, 643-650
CrossRef473
David L. Bartlett, Jordan Berlin, Gregory Y. Lauwers, Wells A. Messersmith, Nicholas J. Petrelli, Alan P. Venook. (2006) Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement. Annals of Surgical Oncology 13:10, 1284-1292
CrossRef474
V Voelter, A Zouhair, H Vuilleumier, M Matter, H Bouzourene, S Leyvraz, J Bauer, P Coucke, R Stupp. (2006) CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II. British Journal of Cancer 95:6, 710-716
CrossRef475
M Wasif Saif. (2006) Hypersensitivity reactions associated with oxaliplatin. Expert Opinion on Drug Safety 5:5, 687-694
CrossRef476
Julia Draznin, Weijing Sun. (2006) Cancers of the bowel and hepatobiliary tract. Update on Cancer Therapeutics 1:3, 353-365
CrossRef477
Kent R Johnson, Clare Ringland, Barrie J Stokes, Danielle M Anthony, Nick Freemantle, Alar Irs, Suzanne R Hill, Robyn L Ward. (2006) Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. The Lancet Oncology 7:9, 741-746
CrossRef478
Wolfram Goessling, Robert J. Mayer. (2006) Systemic Treatment of Patients Who Have Colorectal Cancer and Inflammatory Bowel Disease. Gastroenterology Clinics of North America 35:3, 713-727
CrossRef479
Lara Maria Pasetto, Mario Rosario D’Andrea, Elena Rossi, Silvio Monfardini. (2006) Oxaliplatin-related neurotoxicity: How and why?. Critical Reviews in Oncology/Hematology 59:2, 159-168
CrossRef480
Dulabh K. Monga, Michael J. O’Connell. (2006) Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions. Annals of Surgical Oncology 13:8, 1021-1034
CrossRef481
Francesco Stipa, David B. Chessin, Jinru Shia, Philip B. Paty, Martin Weiser, Larissa K. F. Temple, Bruce D. Minsky, W. Douglas Wong, Jose G. Guillem. (2006) A Pathologic Complete Response of Rectal Cancer to Preoperative Combined-Modality Therapy Results in Improved Oncological Outcome Compared With Those Who Achieve No Downstaging on the Basis of Preoperative Endorectal Ultrasonography. Annals of Surgical Oncology 13:8, 1047-1053
CrossRef482
Neela Natarajan, Todd D. Shuster. (2006) New Agents, Combinations, and Opportunities in the Treatment of Advanced and Early-Stage Colon Cancer. Surgical Clinics of North America 86:4, 1023-1043
CrossRef483
M Saunders, T Iveson. (2006) Management of advanced colorectal cancer: state of the art. British Journal of Cancer 95:2, 131-138
CrossRef484
Macdonald, John S., . (2006) Gastric Cancer — New Therapeutic Options. New England Journal of Medicine 355:1, 76-77
Full Text485
Leonard L. Gunderson, Matthew Callister, Robert Marschke, Tonia Young-Fadok, Jacques Heppell, Jonathan Efron. (2006) Stratifying risks for patients with localized rectal cancer: Do all stage II patients require adjuvant radiation or chemoradiation?. Current Colorectal Cancer Reports 2:3, 151-159
CrossRef486
Takumi Ochiai, Kazuhiko Nishimura, Hajime Noguchi, Masayuki Kitajima, Yuko Tsuruoka, Yuka Takahashi, Akira Tsukada, Emiko Watanabe, Isao Nagaoka, Shunji Futagawa. (2006) Prognostic impact of orotate phosphoribosyl transferase activity in resectable colorectal cancers treated by 5-fluorouracil-based adjuvant chemotherapy. Journal of Surgical Oncology 94:1, 45-50
CrossRef487
Ki Young Chung, Leonard B. Saltz. (2006) Oxaliplatin and irinotecan: From advanced to adjuvant therapy of colon cancer. Current Colorectal Cancer Reports 2:3, 142-148
CrossRef488
Cathy Eng, Nabeel Shalan. (2006) Biological agents versus chemotherapy in the treatment of colorectal cancer. Expert Opinion on Pharmacotherapy 7:10, 1251-1271
CrossRef489
Takeo Mori, Teruyuki Hirota, Yasuo Ohashi, Susumu Kodaira. (2006) Significance of Histologic Type of Primary Lesion and Metastatic Lymph Nodes as a Prognostic Factor in Stage III Colon Cancer. Diseases of the Colon & Rectum 49:7, 982-992
CrossRef490
R. M. Glasspool, J. Cassidy. (2006) Oral fluoropyrimidines in the adjuvant therapy of colon cancer. Current Colorectal Cancer Reports 2:3, 137-141
CrossRef491
Lina Silvéra, Gilles Galula, Emmanuel Tiret, Christophe Louvet, Jean-Louis Leroux, Bernard Trutt. (2006) Assessment of management practices for colonic cancer in the Paris metropolitan area in 2002. Gastroentérologie Clinique et Biologique 30:6-7, 852-858
CrossRef492
Daniel Von Hoff. 2006. Horizons for Cancer Chemotherapy (and Nonchemotherapy). , 445-457.
CrossRef493
A Avallone, P Delrio, C Guida, F Tatangelo, A Petrillo, P Marone, L G Cascini, B Morrica, S Lastoria, V Parisi, A Budillon, P Comella. (2006) Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I–II study. British Journal of Cancer 94:12, 1809-1815
CrossRef494
Prajnan Das, John M. Skibber, Miguel A. Rodriguez-Bigas, Barry W. Feig, George J. Chang, Paulo M. Hoff, Cathy Eng, Robert A. Wolff, Nora A. JanJan, Marc E. Delclos, Sunil Krishnan, Lawrence B. Levy, Lee M. Ellis, Christopher H. Crane. (2006) Clinical and Pathologic Predictors of Locoregional Recurrence, Distant Metastasis, and Overall Survival in Patients Treated With Chemoradiation and Mesorectal Excision for Rectal Cancer. American Journal of Clinical Oncology 29:3, 219-224
CrossRef495
Robert C. G. Martin. (2006) Adjuvant Treatment of Stage II Colon Cancer: Is There a True No-Chemotherapy Group?. Annals of Surgical Oncology 13:6, 766-767
CrossRef496
Ki-Young Y. Chung, David Kelsen. (2006) Adjuvant therapy for stage II colorectal cancer: Who and with what?. Current Treatment Options in Gastroenterology 9:3, 272-280
CrossRef497
Samuel Limat, Claire-Hélène Bracco-Nolin, Christine Legat-Fagnoni, Loic Chaigneau, Ulrich Stein, Bernard Huchet, Xavier Pivot, Marie-Christine Woronoff-Lemsi. (2006) Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer. The European Journal of Health Economics 7:2, 107-113
CrossRef498
Thierry André, Daniel Sargent, Josep Tabernero, Michael O’Connell, Marc Buyse, Alberto Sobrero, Jean-Louis Misset, Corrado Boni, Aimery Gramont. (2006) Current Issues in Adjuvant Treatment of Stage II Colon Cancer. Annals of Surgical Oncology 13:6, 887-898
CrossRef499
Daniele Bernardi, Domenico Errante, Umberto Tirelli, Luigi Salvagno, Antonio Bianco, Ian S. Fentiman. (2006) Insight into the treatment of cancer in older patients: Developments in the last decade. Cancer Treatment Reviews 32:4, 277-288
CrossRef500
V. R. Grann, F. M. Muggia. (2006) Completion Rates of Adjuvant Chemotherapy for Colon Cancer: A Historical Perspective. JNCI Journal of the National Cancer Institute 98:9, 570-571
CrossRef501
Robert J. Downey. (2006) Surgery for Colorectal and Sarcomatous Pulmonary Metastases: History, Current Management, and Future Directions. Thoracic Surgery Clinics 16:2, 133-137
CrossRef502
Ina C. Nordman, Shoba Iyer, Anthony M. Joshua, Stephen J. Clarke. (2006) ADVANCES IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER. ANZ Journal of Surgery 76:5, 373-380
CrossRef503
Peng-Chan Lin, Ming-Yang Lee, Wei-Shu Wang, Chueh-Chuan Yen, Ta-Chung Chao, Liang-Tsai Hsiao, Muh-Hwa Yang, Po-Min Chen, Kon-Ping Lin, Tzeon-Jye Chiou. (2006) N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Supportive Care in Cancer 14:5, 484-487
CrossRef504
Jeffrey Cilley, Mary F. Mulcahy. (2006) Adjuvant therapy for colon cancer. Current Oncology Reports 8:3, 161-166
CrossRef505
Wendy Kelder, Geke A P Hospers, John T M Plukker. (2006) Effects of 5-fluorouracil adjuvant treatment of colon cancer. Expert Review of Anticancer Therapy 6:5, 785-794
CrossRef506
Prajnan Das, Christopher H. Crane. (2006) Preoperative and adjuvant treatment of localized rectal cancer. Current Oncology Reports 8:3, 167-173
CrossRef507
K. Oechsle, G. Schuch, C. Bokemeyer. (2006) Studien zum Kolorektalkarzinom. Der Onkologe 12:4, 345-349
CrossRef508
Maria Serova, Fabien Calvo, François Lokiec, Florence Koeppel, Virginie Poindessous, Annette K. Larsen, Emily S. Van. Laar, Stephen J. Waters, Esteban Cvitkovic, Eric Raymond. (2006) Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemotherapy and Pharmacology 57:4, 491-499
CrossRef509
Hirotoshi Kobayashi, Hideki Ueno, Yojiro Hashiguchi, Hidetaka Mochizuki. (2006) Distribution of lymph node metastasis is a prognostic index in patients with stage III colon cancer. Surgery 139:4, 516-522
CrossRef510
T Kagaya, Y Nakamoto, Y Sakai, T Tsuchiyama, H Yagita, N Mukaida, S Kaneko. (2006) Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer. Cancer Gene Therapy 13:4, 357-366
CrossRef511
Junichi Sakamoto, Satoshi Morita, Koji Oba, Takanori Matsui, Michiya Kobayashi, Hiroaki Nakazato, Yasuo Ohashi, . (2006) Efficacy of adjuvant Immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunology, Immunotherapy 55:4, 404-411
CrossRef512
B. Teleky, Irene Kührer. (2006) Surgical management of cancer of the colon. European Surgery 38:2, 124-128
CrossRef513
Marcia L. McGory, David S. Zingmond, Evan Sekeris, Roshan Bastani, Clifford Y. Ko. (2006) A Patient's Race/Ethnicity Does Not Explain the Underuse of Appropriate Adjuvant Therapy in Colorectal Cancer. Diseases of the Colon & Rectum 49:3, 319-329
CrossRef514
Shimul A. Shah, Riad Haddad, Wigdan Al-Sukhni, Robin D. Kim, Paul D. Greig, David R. Grant, Bryce R. Taylor, Bernard Langer, Steven Gallinger, Alice C. Wei. (2006) Surgical Resection of Hepatic and Pulmonary Metastases from Colorectal Carcinoma. Journal of the American College of Surgeons 202:3, 468-475
CrossRef515
Tara Beers Gibson, Aarati Ranganathan, Amy D'Orazio, Edward Chu, Carlos Becerra. (2006) Highlights From: The 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium San Francisco, CA, January 2006. Clinical Colorectal Cancer 5:6, 398-402
CrossRef516
D B Longley, T R Wilson, M McEwan, W L Allen, U McDermott, L Galligan, P G Johnston. (2006) c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25:6, 838-848
CrossRef517
Justina Martinez, Claudio Martin, Matias Chacon, Ernesto Korbenfeld, Santiago Bella, Susana Senna, Eduardo Richardet, Federico Coppola, Carlos Bas, Jorge Hidalgo, Emiliano Escobar, Monica Reale, Andres M. Smilovich, Ernesto Wasserman. (2006) Irinotecan, Oxaliplatin Plus Bolus 5-Fluorouracil and Low Dose Folinic Acid Every 2 Weeks. American Journal of Clinical Oncology 29:1, 45-51
CrossRef518
E. Aranda, A. Abad, A. Carrato, A. Cervantes, J. Tabernero, E. Díaz-Rubio. (2006) Guides for adjuvant treatment of colon cancer. Clinical and Translational Oncology 8:2, 98-102
CrossRef519
Chiara Carlomagno, Michele Orditura, Stefano Pepe, Ferdinando De Vita, Carmela Romano, Fortunato Ciardiello, Claudia Ferrara, Erika Martinelli, Roberto Bianco, Gaetano Aurilio, Diego D??Agostino, Giampaolo Tortora, Giuseppe Catalano, Sabino De Placido. (2006) Capecitabine Plus Weekly Oxaliplatin in Gastrointestinal Tumors. American Journal of Clinical Oncology 29:1, 85-89
CrossRef520
Thomas Lam, John W. Hetherington, John Greenman, Anthony Maraveyas. (2006) From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. Anti-Cancer Drugs 17:2, 113-121
CrossRef521
Daniel B. Brown, Jean-Francois H. Geschwind, Michael C. Soulen, Steven F. Millward, David Sacks. (2006) Society of Interventional Radiology Position Statement on Chemoembolization of Hepatic Malignancies. Journal of Vascular and Interventional Radiology 17:2, 217-223
CrossRef522
Antoine Italiano. (2006) Targeting the Epidermal Growth Factor Receptor in Colorectal Cancer: Advances and Controversies. Oncology 70:3, 161-167
CrossRef523
Steven L. Chen, Anton J. Bilchik. (2006) More Extensive Nodal Dissection Improves Survival for Stages I to III of Colon Cancer. Transactions of the ... Meeting of the American Surgical Association 124, 267-275
CrossRef524
Irene Kuehrer. (2006) Multimodal treatment of metastatic colorectal cancer. Acta chirurgica iugoslavica 53:2, 51-55
CrossRef525
Anne Vessières, Siden Top, Wolfgang Beck, Elizabeth Hillard, Gérard Jaouen. (2006) Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects. Dalton Transactions:4, 529
CrossRef526
R Bendardaf. (2006) Colorectal Cancer: From Epidemiology to Current Treatment. Libyan Journal of Medicine 1:1, 42-59
CrossRef527
Jane Choi, Kevin Kong, Tahseen Mozaffar, Randall F. Holcombe. (2006) Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anti-Cancer Drugs 17:1, 103-105
CrossRef528
Alberto Pietrangeli, Massimo Leandri, Edmondo Terzoli, Bruno Jandolo, Carlo Garufi. (2006) Persistence of High-Dose Oxaliplatin-Induced Neuropathy at Long-Term Follow-Up. European Neurology 56:1, 13-16
CrossRef529
(2006) Abstracts. Cancer Investigation 24:s1, 5-64
CrossRef530
Heinz Becker, Torsten Liersch. 2006. Kolonkarzinom. , 579-600.
CrossRef531
Duk-Joo Lee, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Myung-Ju Ahn. (2006) Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as Second Line Therapy. Cancer Research and Treatment 38:4, 201
CrossRef532
Vincenzo Dongiovanni, Maria Teresa Spinnler, Mara Ardine. (2006) Feasibility of 5-Fluorouracil resumption in a patient experiencing drug-induced acute Prinzmetal angina. Acta Oncologica 45:2, 220-221
CrossRef533
C. Lamberti, T. Sauerbruch, A Glasmacher. (2005) Adjuvant capecitabine is at least as effective as fluorouracil plus leucovorin for survival in people with resected stage III colon cancer. Cancer Treatment Reviews 31:8, 648-652
CrossRef534
Aimery de Gramont. (2005) Adjuvant Therapy of Stage II and III Colon Cancer. Seminars in Oncology 32, 11-14
CrossRef535
Richard G Webster, Keith L Brain, Richard H Wilson, Jean L Grem, Angela Vincent. (2005) Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. British Journal of Pharmacology 146:7, 1027-1039
CrossRef536
Alain Barrier, Pierre-Yves Boelle, Antoinette Lemoine, Chantal Tse, Didier Brault, Franck Chiappini, François Lacaine, Sidney Houry, Michel Huguier, Antoine Flahault, Sandrine Dudoit. (2005) Gene Expression Profiling of Nonneoplastic Mucosa May Predict Clinical Outcome of Colon Cancer Patients. Diseases of the Colon & Rectum 48:12, 2238-2248
CrossRef537
D. Lawes, I. Taylor. (2005) Chemotherapy for colorectal cancer—an overview of current management for surgeons. European Journal of Surgical Oncology (EJSO) 31:9, 932-941
CrossRef538
Paul H. Sugarbaker. (2005) Decreasing the Risk of a Treatment Expands Its Indications. Annals of Surgical Oncology 12:11, 868-870
CrossRef539
Thomas Knösel, Karsten Schlüns, Manfred Dietel, Iver Petersen. (2005) Chromosomal Alterations in Lung Metastases of Colorectal Carcinomas: Associations with Tissue Specific Tumor Dissemination. Clinical & Experimental Metastasis 22:7, 533-538
CrossRef540
Gunnar Folprecht, Claus-Henning Köhne. (2005) Drug Insight: metastatic colorectal cancer—oral fluoropyrimidines and new perspectives in the adjuvant setting. Nature Clinical Practice Oncology 2:11, 578-587
CrossRef541
D Sebag-Montefiore, R Glynne-Jones, S Falk, H M Meadows, T Maughan. (2005) A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study. British Journal of Cancer 93:9, 993-998
CrossRef542
Ylva Almqvist, Anna Orlova, Anna Sjöström, Holger J. Jensen, Hans Lundqvist, Anders Sundin, Vladimir Tolmachev. (2005) In Vitro Characterization of 211 At-Labeled Antibody A33—a Potential Therapeutic Agent Against Metastatic Colorectal Carcinoma. Cancer Biotherapy & Radiopharmaceuticals 20:5, 514-523
CrossRef543
S. Aguiar, A. Lopes, F.A. Soares, B.M. Rossi, F.O. Ferreira, W.T. Nakagawa, A.L. Carvalho, W.J.D. Filho. (2005) Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancer. European Journal of Surgical Oncology (EJSO) 31:8, 863-868
CrossRef544
Alain Barrier, Antoinette Lemoine, Pierre-Yves Boelle, Chantal Tse, Didier Brault, Franck Chiappini, Julia Breittschneider, François Lacaine, Sidney Houry, Michel Huguier, Mark J Van der Laan, Terry Speed, Brigitte Debuire, Antoine Flahault, Sandrine Dudoit. (2005) Colon cancer prognosis prediction by gene expression profiling. Oncogene 24:40, 6155-6164
CrossRef545
Pascal Artru, Gérard Lledo. (2005) Traitement adjuvant du cancer du côlon à l’asco 2005: L’oxaliplatine accroît sa suprématie!. Acta Endoscopica 35:4, 710-710
CrossRef546
Michael J Martin. (2005) Current stage-specific chemotherapeutic options in colon cancer. Expert Review of Anticancer Therapy 5:4, 695-704
CrossRef547
Karl-Heinz Link, Marko Kornmann, Ludger Staib, Martin Redenbacher, Martina Kron, Hans G??nter Beger. (2005) Increase of Survival Benefit in Advanced Resectable Colon Cancer by Extent of Adjuvant Treatment. Annals of Surgery 242:2, 178-187
CrossRef548
E. Bölke, M. Wettstein, W. Budach. (2005) Neoadjuvate und adjuvante Radio- und Radiochemotherapie beim Rektumkarzinom. Der Onkologe 11:8, 822-831
CrossRef549
F Lordick, S Lorenzen, J Stollfuss, U Vehling-Kaiser, F Kullmann, M Hentrich, R Zumschlinge, H Dietzfelbinger, J Thoedtmann, M Hennig, T Seroneit, R Bredenkamp, J Duyster, C Peschel. (2005) Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. British Journal of Cancer 93:2, 190-194
CrossRef550
Wim Veldhuis. (2005) Klachten in de palliatieve fase: niet alles is wat het lijkt. Huisarts en Wetenschap 48:7, 537-539
CrossRef551
Arun V. Krishnan, David Goldstein, Michael Friedlander, Matthew C. Kiernan. (2005) Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle & Nerve 32:1, 51-60
CrossRef552
G. Kesava Reddy, Edward Chu. (2005) Recent Data with Oxaliplatin-Containing Regimens in the Adjuvant Treatment of Colorectal Cancer. Clinical Colorectal Cancer 5:2, 83-85
CrossRef553
Bernard Nordlinger, Philippe Rougier, Jean-Pierre Arnaud, Muriel Debois, Jaques Wils, Jean-Claude Ollier, Olivier Grobost, Philippe Lasser, Jacob Wals, Jerome Lacourt, Jean-François Seitz, Jose Guimares dos Santos, Harry Bleiberg, Rémy Mackiewickz, Thierry Conroy, Olivier Bouché, Thierry Morin, Liliana Baila, Eric van Cutsem, Laurent Bedenne. (2005) Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II–III colorectal cancer: a multicentre randomised controlled phase III trial. The Lancet Oncology 6:7, 459-468
CrossRef554
Preeta Tyagi, Edward Chu. (2005) Adjuvant Irinotecan Regimens in Combination with Infusional 5-Fluorouracil/Leucovorin Fail to Improve Outcomes in Surgically Resected Colorectal Cancer. Clinical Colorectal Cancer 5:2, 86-88
CrossRef555
Twelves, Chris, Wong, Alfred, Nowacki, Marek P., Abt, Markus, Burris, Howard III, Carrato, Alfredo, Cassidy, Jim, Cervantes, Andrés, Fagerberg, Jan, Georgoulias, Vassilis, Husseini, Fares, Jodrell, Duncan, Koralewski, Piotr, Kröning, Hendrik, Maroun, Jean, Marschner, Norbert, McKendrick, Joseph, Pawlicki, Marek, Rosso, Riccardo, Schüller, Johannes, Seitz, Jean-François, Stabuc, Borut, Tujakowski, Jerzy, Van Hazel, Guy, Zaluski, Jerzy, Scheithauer, Werner, . (2005) Capecitabine as Adjuvant Treatment for Stage III Colon Cancer. New England Journal of Medicine 352:26, 2696-2704
Full Text556
Allegra, Carmen, Sargent, Daniel J., . (2005) Adjuvant Therapy for Colon Cancer — The Pace Quickens. New England Journal of Medicine 352:26, 2746-2748
Full Text557
Antonello D'Arrigo, Claudio Belluco, Alessandro Ambrosi, Maura Digito, Giovanni Esposito, Antonella Bertola, Michele Fabris, Valentina Nofrate, Enzo Mammano, Alberta Leon, Donato Nitti, Mario Lise. (2005) Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. International Journal of Cancer 115:2, 256-262
CrossRef558
Joseph McKendrick, John Coutsouvelis. (2005) Capecitabine: effective oral fluoropyrimidine chemotherapy. Expert Opinion on Pharmacotherapy 6:7, 1231-1239
CrossRef559
Weijing Sun, Daniel G. Haller. (2005) Adjuvant therapy for colon cancer. Current Oncology Reports 7:3, 181-185
CrossRef560
Massimo Magagnoli, Giovanna Masci, Luca Castagna, Stefania Bramanti, Emanuela Morenghi, Carlo Carnaghi, Armando Santoro. (2005) High incidence of haemostatic interference in cancer patients treated with FOLFOX regimen and concomitant minidose of warfarin. British Journal of Haematology 129:5, 709-710
CrossRef561
Sharlene Gill, Richard M Goldberg. (2005) Duration of adjuvant therapy for colorectal cancer: are we overtreating our patients?. Nature Clinical Practice Oncology 2:6, 276-277
CrossRef562
Szilvia Mosolits, Bo Nilsson, Håkan Mellstedt. (2005) Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Review of Vaccines 4:3, 329-350
CrossRef563
Viktor Brabec, Jana Kasparkova. (2005) Modifications of DNA by platinum complexes. Drug Resistance Updates 8:3, 131-146
CrossRef564
G. Chong, D. Cunningham. (2005) Gastrointestinal cancer: recent developments in medical oncology. European Journal of Surgical Oncology (EJSO) 31:5, 453-460
CrossRef565
Farid E Ahmed. (2005) Molecular markers that predict response to colon cancer therapy. Expert Review of Molecular Diagnostics 5:3, 353-375
CrossRef566
VJ O'Neill, J Cassidy. (2005) Capecitabine in the treatment of colorectal cancer. Future Oncology 1:2, 183-190
CrossRef567
D Goldstein, P Mitchell, M Michael, P Beale, M Friedlander, J Zalcberg, S White, S Clarke. (2005) Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. British Journal of Cancer 92:5, 832-837
CrossRef568
Bert H. OʼNeil, Joel E. Tepper. (2005) Gemcitabine Radiosensitization for Rectal Cancer. The Cancer Journal 11:2, 110-112
CrossRef569
Hanna Kelly, Bert H. O’Neil, Richard M. Goldberg. (2005) Optimizing adjuvant therapy for colon cancer: Ongoing investigations. Current Colorectal Cancer Reports 1:1, 27-33
CrossRef570
G. Kesava Reddy, Tara Beers Gibson, Susan Peck, Preeta Tyagi, Edward Chu, Sara Mariani. (2005) Highlights From: The American Society of Clinical Oncology Gastrointestinal Cancers Symposium; Hollywood, FL January 2005. Clinical Colorectal Cancer 4:6, 367-374
CrossRef571
Mohamed Hebbar. (2005) Chemotherapy in patients with resectable liver metastases from colorectal cancer. Current Colorectal Cancer Reports 1:1, 34-40
CrossRef572
David P. Ryan. (2005) The integration of biologic agents into the current systemic management of rectal cancer. Current Colorectal Cancer Reports 1:1, 58-62
CrossRef573
Brian HC LE, Surender JUNEJA, Peter GIBBS. (2005) Hemolysis and thrombocytopenia following oxaliplatin administration. Asia-Pacific Journal of Clinical Oncology 1:1, 57-60
CrossRef574
Meyerhardt, Jeffrey A., Mayer, Robert J., . (2005) Systemic Therapy for Colorectal Cancer. New England Journal of Medicine 352:5, 476-487
Full Text575
Luis A. Diaz. (2005) The current clinical value of genomic instability. Seminars in Cancer Biology 15:1, 67-71
CrossRef576
Weijing Sun, Daniel G. Haller. (2005) Adjuvant therapy of colon cancer. Seminars in Oncology 32:1, 95-102
CrossRef577
A Sobrero, G Frassineti, A Falcone, L Dogliotti, R Rosso, F D Costanzo, P Bruzzi. (2005) Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer. British Journal of Cancer 92:1, 24-29
CrossRef578
YUTAKA OGATA, SHOJIRO TORIGOE, KEIKO MATONO, TERUO SASATOMI, NOBUYA ISHIBASHI, SEIICHIRO SHIDA, AKIRA OHKITA, TOMOAKI MIZOBE, SATORU IKEDA, SHUJIRO OGOU, HIROYUKI OZASA, KAZUO SHIROUZU. (2005) Prognostic Factors after Potentially Curative Resection in Stage II or III Colon Cancer. The Kurume Medical Journal 52:3, 67-71
CrossRef579
Sandeep Goyle, Anthony Maraveyas. (2005) Chemotherapy for Colorectal Cancer. Digestive Surgery 22:6, 401-414
CrossRef580
Daniele Santini, Bruno Vincenzi, Annalisa La Cesa, Marco Caricato, Gaia Schiavon, Bruno Spalletta, Marisa Di Seri, Roberto Coppola, Laura Rocci, Giuseppe Tonini. (2005) Continuous Infusion of Oxaliplatin plus Chronomodulated Capecitabine in 5-Fluorouracil- and Irinotecan-Resistant Advanced Colorectal Cancer Patients. Oncology 69:1, 27-34
CrossRef581
YUTAKA OGATA, KEIKO MATONO, SHOJIRO TORIGOE, TOMOAKI MIZOBE, TERUO SASATOMI, NOBUYA ISHIBASHI, SEIICHIRO SHIDA, AKIRA OHKITA, TAKAMASA FUKUMITU, SATORU IKEDA, SHUJIRO OGO, HIROYUKI OZASA, KAZUO SHIROUZU. (2005) The Benefit of Post-Operative Adjuvant Chemotherapy Using Oral Fluoropyrimidines in Rectal Cancer. The Kurume Medical Journal 52:1/2, 1-7
CrossRef582
Jürgen Weitz, Moritz Koch, Jürgen Debus, Thomas Höhler, Peter R Galle, Markus W Büchler. (2005) Colorectal cancer. The Lancet 365:9454, 153-165
CrossRef583
Susan J Keam, Christopher J Dunn, David P Figgitt. (2005) Oxaliplatin. Drugs 65:1, 89-96
CrossRef584
Claus-Henning Köhne. (2005) Stellenwert der intensivierten Chemotherapie und der neuen Substanzen in der adjuvanten und palliativen Situation beim kolorektalen Karzinom. Chirurgische Gastroenterologie 21:2, 145-150
CrossRef585
G. Hartung, R-D. Hofheinz, Y. Dencausse, J. Sturm, A. Kopp-Schneider, G. Dietrich, I. Fackler-Schwalbe, D. Bornbusch, M. Gonnermann, C. Wojatschek, W. Lindemann, H. Eschenburg, K. Jost, L. Edler, A. Hochhaus, W. Queißer. (2005) Adjuvant Therapy with Edrecolomab versus Observation in Stage II Colon Cancer: A Multicenter Randomized Phase III Study*. Onkologie 28:6-7, 347-350
CrossRef586
Ashita M Waterston, Jim Cassidy. (2005) Adjuvant Treatment Strategies for Early Colon Cancer. Drugs 65:14, 1935-1947
CrossRef587
Michael A. Choti. (2004) Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer. Cancer Treatment Reviews 30:8, 715-720
CrossRef588
Howard Ozer, Robert B. Diasio. (2004) Perspectives in the treatment of colorectal cancer. Seminars in Oncology 31, 14-18
CrossRef589
Syma Iqbal, Heinz-Josef Lenz. (2004) Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. Expert Review of Anticancer Therapy 4:6, 947-955
CrossRef590
Neil H. Hyman. (2004) What’s new in colon and rectal surgery. Journal of the American College of Surgeons 199:6, 917-923
CrossRef591
Daniel G. Haller. (2004) Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers. Seminars in Oncology 31, 10-16
CrossRef592
Sheila A Doggrell. (2004) Which drug combination for colorectal cancer?. Expert Opinion on Pharmacotherapy 5:12, 2621-2624
CrossRef593
Paulo M Hoff. (2004) Oxaliplatin-related neurotoxicity: is chelation the solution?. Nature Clinical Practice Oncology 1:2, 78-79
CrossRef594
(2004) Scientific surgery. British Journal of Surgery 91:12, 1656-1656
CrossRef595
G. Kesava Reddy, Edward Chu. (2004) Intergroup Trial Fails to Demonstrate a Benefit with the Addition of Irinotecan to Bolus 5-Fluorouracil/Leucovorin in Stage III Colon Cancer. Clinical Colorectal Cancer 4:4, 230-232
CrossRef596
(2004) Oxaliplatin in Colon Cancer. New England Journal of Medicine 351:16, 1691-1692
Full Text597
Axel Grothey, Richard M Goldberg. (2004) A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opinion on Pharmacotherapy 5:10, 2159-2170
CrossRef598
Andrea Formentini, Doris Henne-Bruns, Marko Kornmann. (2004) Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. Langenbeck's Archives of Surgery 389:5, 405-413
CrossRef599
S Ohwada, Y Morishita. (2004) Reply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer. British Journal of Cancer
CrossRef600
Matthew P Goetz, Axel Grothey. (2004) Developments in combination chemotherapy for colorectal cancer. Expert Review of Anticancer Therapy 4:4, 627-637
CrossRef601
G BERETTA, L MILESI, M PESSI, S MOSCONI, R LABIANCA. (2004) Adjuvant treatment of colorectal cancer. Surgical Oncology 13:2-3, 63-73
CrossRef602
Mayer, Robert J., . (2004) Two Steps Forward in the Treatment of Colorectal Cancer. New England Journal of Medicine 350:23, 2406-2408
Full Text
- Letters
